<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochemistry</journal-id><journal-id journal-id-type="iso-abbrev">Biochemistry</journal-id><journal-id journal-id-type="publisher-id">bi</journal-id><journal-id journal-id-type="coden">bichaw</journal-id><journal-title-group><journal-title>Biochemistry</journal-title></journal-title-group><issn pub-type="ppub">0006-2960</issn><issn pub-type="epub">1520-4995</issn><publisher><publisher-name>American
Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25268459</article-id><article-id pub-id-type="pmc">4211652</article-id><article-id pub-id-type="doi">10.1021/bi5005552</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Covalent Small Molecule Inhibitors of Ca<sup>2+</sup>-Bound S100B</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Cavalier</surname><given-names>Michael
C.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Pierce</surname><given-names>Adam D.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Wilder</surname><given-names>Paul T.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Alasady</surname><given-names>Milad J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Hartman</surname><given-names>Kira G.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Neau</surname><given-names>David B.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Foley</surname><given-names>Timothy L.</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Jadhav</surname><given-names>Ajit</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Maloney</surname><given-names>David J.</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Simeonov</surname><given-names>Anton</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Toth</surname><given-names>Eric A.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath12"><name><surname>Weber</surname><given-names>David J.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Center
for Biomolecular Therapeutics (CBT), Department of Biochemistry and
Molecular Biology, <institution>University of Maryland
School of Medicine</institution>, Baltimore, Maryland 21201, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Marlene
and Stewart Greenebaum Cancer Center, <institution>University
of Maryland School of Medicine</institution>, Baltimore, Maryland 21201, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label>NE-CAT, <institution>Cornell
University</institution>, Argonne, Illinois 60439, <country>United
States</country></aff><aff id="aff4"><label>&#x02225;</label>National
Center for Advancing Translational Sciences, <institution>National Institutes of Health</institution>, Bethesda, Maryland 20892, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>University of Maryland School of
Medicine, Department of Biochemistry and Molecular Biology, Biomedical
Research Facility, Rm. 439, 108 N. Greene St., Baltimore, MD 21201.
E-mail: <email>dweber@som.umaryland.edu</email>. Phone: <phone>(410)
706-4354</phone>. Fax: <fax>(410) 706-0438</fax>.</corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>09</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2014</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>10</month><year>2014</year></pub-date><volume>53</volume><issue>42</issue><fpage>6628</fpage><lpage>6640</lpage><history><date date-type="received"><day>09</day><month>05</month><year>2014</year></date><date date-type="rev-recd"><day>30</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 American Chemical
Society</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Chemical
Society</copyright-holder><license><license-p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">Terms of Use</ext-link></license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0010" id="ab-tgr1"/></p><p>Elevated levels of the tumor marker
S100B are observed in malignant
melanoma, and this EF-hand-containing protein was shown to directly
bind wild-type (wt) p53 in a Ca<sup>2+</sup>-dependent manner, dissociate
the p53 tetramer, and inhibit its tumor suppression functions. Likewise,
inhibiting S100B with small interfering RNA (siRNA<sup>S100B</sup>) is sufficient to restore wild-type p53 levels and its downstream
gene products and induce the arrest of cell growth and UV-dependent
apoptosis in malignant melanoma. Therefore, it is a goal to develop
S100B inhibitors (SBi<italic>X</italic>s) that inhibit the S100B&#x02013;p53
complex and restore active p53 in this deadly cancer. Using a structure&#x02013;activity
relationship by nuclear magnetic resonance approach (SAR by NMR),
three persistent binding pockets are found on S100B, termed sites
1&#x02013;3. While inhibitors that simultaneously bind sites 2 and
3 are in place, no molecules that simultaneously bind all three persistent
sites are available. For this purpose, Cys84 was used in this study
as a potential means to bridge sites 1 and 2 because it is located
in a small crevice between these two deeper pockets on the protein.
Using a fluorescence polarization competition assay, several Cys84-modified
S100B complexes were identified and examined further. For five such
SBi<italic>X</italic>&#x02013;S100B complexes, crystallographic structures
confirmed their covalent binding to Cys84 near site 2 and thus present
straightforward chemical biology strategies for bridging sites 1 and
3. Importantly, one such compound, SC1982, showed an S100B-dependent
death response in assays with WM115 malignant melanoma cells, so it
will be particularly useful for the design of SBi<italic>X</italic> molecules with improved affinity and specificity.</p></abstract><funding-group><funding-statement><funding-source>National Institutes of Health, United States</funding-source></funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>bi5005552</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>bi-2014-005552</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Despite improvements
in chemotherapy,
BRAF/MEK inhibitors, cytokine treatments, immunotherapies, vaccines,
and combinatorial approaches for treating malignant melanoma (MM),<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> long-term survival (&#x0003e;3 years) remains very poor for a majority
of
patients (&#x0003e;70%), and side effects from these treatments are sometimes
quite severe.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> These
issues are even more problematic after the onset of metastasis and/or
when drug-resistant mechanisms arise.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> As with many
cancers, survival from MM is most promising when it is detected early,
so the development of useful biomarkers for detection and more recently
for personalized medicine approaches is ongoing.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> One
such marker, S100B, is especially important to monitor because its
level is elevated in &#x0003e;90% of MM patients and its protein level
correlates
directly with poor survival (&#x0003c;1 year) and relapse, and it is especially
predictive when used in combination with other diagnostic indicators.<sup><xref ref-type="bibr" rid="ref11">11</xref>&#x02212;<xref ref-type="bibr" rid="ref13">13</xref></sup> On the other hand, for the few MM patients (5&#x02013;10%) who have
low levels of S100B, the MM vaccine is most effective at providing
longer survival times.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup></p><p>The S100B protein is a
marker for melanoma, and when its level
is elevated, it contributes to disease progression.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> While the mechanism of elevated S100B levels toward MM progression
is not fully understood, it contributes to lowering protein levels
of the tumor suppressor p53 in a Ca<sup>2+</sup>-dependent manner.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> Specifically, p53 is sequestered by Ca<sup>2+</sup>-bound S100B
(<sup>Ca</sup>S100B), its phosphorylation in the C-terminal negative
regulator domain blocked,<sup><xref ref-type="bibr" rid="ref20">20</xref>&#x02212;<xref ref-type="bibr" rid="ref23">23</xref></sup> its oligomerization disrupted,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and its degradation promoted.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup> Because p53
is typically wild-type in MM,<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> efforts are underway
to specifically inhibit formation of the <sup>Ca</sup>S100B&#x02013;p53
complex<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> and restore
p53 levels, particularly in cases in which the cancer is resistant
to kinase inhibitors or other therapeutic options.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> As a proof of principle, blocking the <sup>Ca</sup>S100B-dependent
effect on p53 via RNA interference or by small molecule inhibitors
(also known as SBi<italic>X</italic>s) restores p53 protein levels
and its tumor suppression activities, including UV-activated apoptosis.<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup> One such inhibitor, pentamidine
(also termed SBi1), entered stage II clinical trials for the treatment
of relapsed or refractory malignant melanoma in patients with wild-type
p53 and detectable S100B (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</uri>, identifier
NCT00729807). However, despite this promising line of inquiry, efficacy,
specificity, and toxicity issues need to be improved significantly
for SBi<italic>X</italic> lead molecules and warrant further investigation
using drug design approaches.</p><p>In previous structure&#x02013;function
studies of S100B,<sup><xref ref-type="bibr" rid="ref32">32</xref>&#x02212;<xref ref-type="bibr" rid="ref35">35</xref></sup> three persistent binding sites were identified in <sup>Ca</sup>S100B&#x02013;target
and <sup>Ca</sup>S100B&#x02013;SBi<italic>X</italic> complexes (Figure <xref rid="fig1" ref-type="fig">1</xref>). Site 1 interactions were first highlighted via
the structure of <sup>Ca</sup>S100B bound to the C-terminal regulatory
domain of p53,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> while sites 2 and 3 were
elucidated in the detailed characterization of the <sup>Ca</sup>S100B&#x02013;SBi1
complex.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Here we describe a series of
inhibitors, which occupy only the central binding site on <sup>Ca</sup>S100B (site 2) through a covalent attachment to Cys84. To fully characterize
this binding site, a series of &#x0201c;site 2&#x0201d; <sup>Ca</sup>S100B&#x02013;SBi<italic>X</italic> complexes were subjected to crystallization
trials. Five new <sup>Ca</sup>S100B&#x02013;SBi<italic>X</italic> complexes
were identified (i.e., for <sup>Ca</sup>S100B&#x02013;SC124, <sup>Ca</sup>S100B&#x02013;SBi4172, <sup>Ca</sup>S100B&#x02013;SC1982, and <sup>Ca</sup>S100B&#x02013;SC1475). As a group, these &#x0201c;site 2&#x0201d;
inhibitors display a meaningful effect in cellular assays on their
own, but as discussed here, they also provide promise for defining
how to link SBi<italic>X</italic> molecules bound in sites 1 and 3,
as part of a new chemical scaffold, which can occupy all three persistent
binding pockets within <sup>Ca</sup>S100B, simultaneously. These data
also identify a common conformational change that occurs as a result
of &#x0201c;site 2&#x0201d; occupation, which is necessary to consider
in future therapeutic design efforts.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Binding sites 1&#x02013;3. Shown is a ribbon
diagram of the S100B
dimer with the three persistent binding sites shaded. The sites were
identified in <sup>Ca</sup>S100B&#x02013;target and <sup>Ca</sup>S100B&#x02013;SBi<italic>X</italic> complexes. Site 1 interactions were first highlighted
via the structure of <sup>Ca</sup>S100B bound to the C-terminal regulatory
domain of p53,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> while sites 2 and 3 were
elucidated in the detailed characterization of the <sup>Ca</sup>S100B&#x02013;SBi1
complex.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0012" id="gr1" position="float"/></fig><sec sec-type="methods" id="sec2"><title>Experimental Procedures</title><sec id="sec2.1"><title>Purification</title><p><sup>15</sup>N-labeled
S100B (rat and
bovine) was expressed and purified (&#x0003e;99%) with methods similar
to
those described previously.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> The concentrations
of S100B stock solutions were determined using the Bio-Rad Protein
Assay (Bio-Rad Inc., Hercules, CA). The S100B was stored at a concentration
of &#x0223c;10 mM in 0.25 mM Tris (pH 7.2) and 0.25 mM DTT at &#x02212;20
&#x000b0;C until use.</p></sec><sec id="sec2.2"><title>Fluorescence Polarization Competition Assay
(FPCA)</title><p>The LOPAC1280 (Sigma-Aldrich) compound library was
screened using
an adaptation of a previously reported fluorescence polarization competition
assay.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Briefly, the compounds were screened
for binding to Ca<sup>2+</sup>-loaded S100B by measuring changes in
fluorescence polarization upon competition with the TAMRA-labeled
version of peptide TRTK12, which is derived from CapZ protein residues
265&#x02013;276 (TRTKIDWNKILS).
The FPCA was performed in 0.2 &#x003bc;M S100B (rat), 25 nM TAMRA-TRTK12,
50 mM HEPES (pH 7.2), 100 mM KCl, 15 mM NaCl, 10 mM CaCl<sub>2</sub>, 0.01% Triton X-100, and 0.3% DMSO in 1536-well plates with 8 &#x003bc;L
per well.</p></sec><sec id="sec2.3"><title>NMR Spectroscopy</title><p>Purified <sup>15</sup>N-labeled S100B
(rat) protein was dialyzed against 0.25 mM Tris (pH 7.5) and 0.25
mM DTT and concentrated to 10&#x02013;15 mM using Amicon Ultra centrifugal
filter units with a 10 kDa molecular weight cutoff; the concentration
was determined using Bradford reagent (Bio-Rad), and protein was then
aliquoted and stored at &#x02212;20 &#x000b0;C. The Ca<sup>2+</sup>-loaded
S100B&#x02013;SBi<italic>X</italic> heteronuclear single-quantum coherence
(HSQC) samples contained 0.5 mM S100B subunit, 0.625 mM SBi<italic>X</italic>, 0.34 mM NaN<sub>3</sub>, 15 mM NaCl, 5% DMSO-<italic>d</italic><sub>6</sub>, 10 mM CaCl<sub>2</sub>, 10% D<sub>2</sub>O, 0.2% TPEN, and 10 mM Hepes, adjusted to pH 7.2 with HCl. HSQC
NMR data were collected at 37 &#x000b0;C with a Bruker Avance 800 US2
(800.27 MHz for protons) instrument equipped with pulsed-field gradients,
four frequency channels, and triple-resonance, <italic>z</italic>-axis
gradient cryogenic probes. Data were processed with NMRPipe, and proton
chemical shifts were reported with respect to the H<sub>2</sub>O or
HDO signal taken as 4.608 ppm relative to external TSP (0.0 ppm).
The <sup>15</sup>N chemical shifts were indirectly referenced as previously
described using the following ratio of the zero-point frequency: 0.10132905
for <sup>15</sup>N to <sup>1</sup>H. A series of three-dimensional
HNCA, HNCOCA, <sup>15</sup>N-edited NOESY-HSQC, and <sup>15</sup>N-edited
HMQC-NOESY-HSQC NMR experiments were conducted, and the data were
sufficient to unambiguously assign all the observable backbone <sup>1</sup>H, <sup>15</sup>N, and <sup>13</sup>C chemical shift values
of S100B in the compound-bound state (Figures S1&#x02013;S5 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p></sec><sec id="sec2.4"><title>Crystallographic Studies</title><sec id="sec2.4.1"><title>Crystallization</title><p>All crystallization experiments were
conducted using vapor diffusion methods and performed as follows using
purified <sup>15</sup>N-labeled S100B (bovine) protein. <sup>Ca</sup>S100B&#x02013;SBi4172 crystals were grown in sitting drops consisting
of a 0.75:0.75 &#x003bc;L protein solution [20 mg/mL S100B, 10 mM cacodylate
(pH 7.2), 7.5 mM CaCl<sub>2</sub>, and 2 mM SBi4172 prepared in DMSO-<italic>d</italic><sub>6</sub>] and mother liquor [20% 2-methyl-2,4-pentanediol,
0.1 M Hepes (pH 7.0), and 7.5 mM CaCl<sub>2</sub>]. <sup>Ca</sup>S100B&#x02013;SBi4434
crystals were grown in sitting drops consisting of a 0.75:0.75 &#x003bc;L
protein solution [40 mg/mL S100B, 10 mM cacodylate (pH 7.2), 7.5 mM
CaCl<sub>2</sub>, and 4 mM SBi4434 prepared in DMSO-<italic>d</italic><sub>6</sub>] and mother liquor [40% 2-methyl-2,4-pentanediol, 0.1
M cacodylate (pH 6.0), and 7.5 mM CaCl<sub>2</sub>]. <sup>Ca</sup>S100B&#x02013;SC1982 crystals were grown in sitting drops consisting
of a 0.75:0.75 &#x003bc;L protein solution [40 mg/mL S100B, 10 mM cacodylate
(pH 7.2), 7.5 mM CaCl<sub>2</sub>, and 4 mM SC1982 prepared in DMSO-<italic>d</italic><sub>6</sub>] and mother liquor [40% 2-methyl-2,4-pentanediol,
0.1 M Tris (pH 8.0), and 7.5 mM CaCl<sub>2</sub>]. <sup>Ca</sup>S100B&#x02013;SC1475
crystals were grown in sitting drops consisting of a 0.75:0.75 &#x003bc;L
protein solution [40 mg/mL S100B, 10 mM cacodylate (pH 7.2), 7.5 mM
CaCl<sub>2</sub>, and 4 mM SC1475 prepared in DMSO-<italic>d</italic><sub>6</sub>] and mother liquor [40% 2-methyl-2,4-pentanediol, 0.1
M Bis-Tris (pH 6.0), and 7.5 mM CaCl<sub>2</sub>]. <sup>Ca</sup>S100B&#x02013;SC124
crystals were grown in sitting drops consisting of a 0.75:0.75 &#x003bc;L
protein solution [40 mg/mL S100B, 10 mM cacodylate (pH 7.2), 7.5 mM
CaCl<sub>2</sub>, and 4 mM SC124 prepared in DMSO-<italic>d</italic><sub>6</sub>] and mother liquor [40% 2-methyl-2,4-pentanediol, 0.1
M Hepes (pH 7.0), and 7.5 mM CaCl<sub>2</sub>]. The crystals were
grown over a period of 1&#x02013;14 days at 295 K. Crystals were flash-cooled
directly from the crystallization drop.</p></sec><sec id="sec2.4.2"><title>Data Collection and Processing</title><p>Diffraction data for <sup>Ca</sup>S100B&#x02013;SBi4172 crystals
were collected at the Northeastern
Collaborative Access Team (NE-CAT) 24ID-C beamline at the Advanced
Photon Source (Argonne National Laboratory, Argonne, IL). Data were
recorded at 100 K on a PILATUS detector and processed by NE-CAT&#x02019;s
RAPD automated processing (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rapd.nec.aps.anl.gov/rapd">https://rapd.nec.aps.anl.gov/rapd</uri>), which uses XDS<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> for integration and
scaling. A 1.73 &#x000c5; data set was collected at a wavelength of 0.97920
&#x000c5; while the crystal was being oscillated by 1.0&#x000b0; each frame.
The space group was determined to be <italic>P</italic>21.</p><p>Diffraction
data for <sup>Ca</sup>S100B&#x02013;SC124, <sup>Ca</sup>S100B&#x02013;SBi4434,
and <sup>Ca</sup>S100B&#x02013;SC1982 crystals were collected remotely<sup><xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref41">41</xref></sup> at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 7-1.
Data were recorded at 100 K on an ADSC Q315 (315 mm &#x000d7; 315 mm)
detector with collection strategies generated by BLU-ICE.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup><sup>Ca</sup>S100B&#x02013;SC124 and <sup>Ca</sup>S100B&#x02013;SC1982 data sets were processed and integrated by AUTOXDS,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> while S100B&#x02013;SBi4434 data sets were processed
and integrated by MOSFLM<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> within the CCP4
program suite.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> A 1.58 &#x000c5; <sup>Ca</sup>S100B&#x02013;SC124 data set was collected at a wavelength of 1.1271
&#x000c5; while the crystal was being oscillated by 0.6&#x000b0; each frame.
The space group was determined to be <italic>P</italic>21. A 1.08
&#x000c5; <sup>Ca</sup>S100B&#x02013;SBi4434 data set was collected at
a wavelength of 1.00 &#x000c5; while the crystal was being oscillated
by 0.35&#x000b0; each frame. The space group was determined to be <italic>P</italic>21. A 1.65 &#x000c5; <sup>Ca</sup>S100B&#x02013;SC1982 data
set was collected at a wavelength of 1.1271 &#x000c5; while the crystal
was being oscillated 0.45&#x000b0; each frame. The space group was determined
to be <italic>C</italic>2221.</p><p>Diffraction data for <sup>Ca</sup>S100B&#x02013;SC1475 crystals
were collected remotely<sup><xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref41">41</xref></sup> at Stanford Synchrotron
Radiation Lightsource (SSRL) beamline 12-2. Data were recorded at
100 K on a PILATUS detector with collection strategies generated by
BLU-ICE,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> and processing and integration
were performed by AUTOXDS.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> A 2.18 &#x000c5;
data set was collected at a wavelength of 0.97950 &#x000c5; while the
crystal was being oscillated by 0.15&#x000b0; each frame. The space group
was determined to be <italic>P</italic>21. Diffraction data statistics
are summarized in Table <xref rid="tbl1" ref-type="other">1</xref>.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Statistics of Reflection Data and
Structure Refinements<xref rid="t1fn88" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">SC124</th><th style="border:none;" align="center">SC1475</th><th style="border:none;" align="center">SC1982</th><th style="border:none;" align="center">SBi4172</th><th style="border:none;" align="center">SBi4434</th></tr></thead><tbody><tr><td style="border:none;" align="left">space group</td><td style="border:none;" align="left"><italic>P</italic>21</td><td style="border:none;" align="left"><italic>P</italic>21</td><td style="border:none;" align="left"><italic>C</italic>2221</td><td style="border:none;" align="left"><italic>P</italic>21</td><td style="border:none;" align="left"><italic>P</italic>21</td></tr><tr><td style="border:none;" align="left">unit cell dimensions (&#x000c5;)</td><td style="border:none;" align="left">34.7, 56.5, 48.3</td><td style="border:none;" align="left">35.0, 58.1, 47.9</td><td style="border:none;" align="left">34.6, 90.0, 60.8</td><td style="border:none;" align="left">35.0, 57.1, 48.0</td><td style="border:none;" align="left">35.2,
56.3, 48.1</td></tr><tr><td style="border:none;" align="left">unit cell angles (deg)</td><td style="border:none;" align="left">90.0, 110.1, 90.0</td><td style="border:none;" align="left">90.0, 111.2, 90.0</td><td style="border:none;" align="left">90.0, 90.0, 90.0</td><td style="border:none;" align="left">90.0, 111.0, 90.0</td><td style="border:none;" align="left">90.0,
108.8, 90.0</td></tr><tr><td style="border:none;" align="left">resolution range (&#x000c5;)</td><td style="border:none;" align="left">35.35&#x02013;1.58</td><td style="border:none;" align="left">35.40&#x02013;2.18</td><td style="border:none;" align="left">36.17&#x02013;1.65</td><td style="border:none;" align="left">44.82&#x02013;1.73</td><td style="border:none;" align="left">21.69&#x02013;1.08</td></tr><tr><td style="border:none;" align="left">no. of reflections observed</td><td style="border:none;" align="left">83472&#x000a0;(9120)</td><td style="border:none;" align="left">30768&#x000a0;(4167)</td><td style="border:none;" align="left">55035&#x000a0;(7875)</td><td style="border:none;" align="left">55396&#x000a0;(8136)</td><td style="border:none;" align="left">244228&#x000a0;(12126)</td></tr><tr><td style="border:none;" align="left">no. of unique
reflections</td><td style="border:none;" align="left">23617&#x000a0;(3115)</td><td style="border:none;" align="left">9152&#x000a0;(1259)</td><td style="border:none;" align="left">11752&#x000a0;(1673)</td><td style="border:none;" align="left">17118&#x000a0;(2517)</td><td style="border:none;" align="left">70592&#x000a0;(3504)</td></tr><tr><td style="border:none;" align="left">no. of reflections in the <italic>R</italic><sub>free</sub> set</td><td style="border:none;" align="left">1201</td><td style="border:none;" align="left">935</td><td style="border:none;" align="left">1173</td><td style="border:none;" align="left">869</td><td style="border:none;" align="left">2006</td></tr><tr><td style="border:none;" align="left">completeness (%)</td><td style="border:none;" align="left">97.8&#x000a0;(89.1)</td><td style="border:none;" align="left">96.7&#x000a0;(91.7)</td><td style="border:none;" align="left">99.9&#x000a0;(99.8)</td><td style="border:none;" align="left">92.6&#x000a0;(94.2)</td><td style="border:none;" align="left">92.2&#x000a0;(93.0)</td></tr><tr><td style="border:none;" align="left">redundancy</td><td style="border:none;" align="left">3.5&#x000a0;(2.9)</td><td style="border:none;" align="left">3.4&#x000a0;(3.3)</td><td style="border:none;" align="left">4.7&#x000a0;(4.7)</td><td style="border:none;" align="left">3.2&#x000a0;(3.2)</td><td style="border:none;" align="left">3.5&#x000a0;(3.5)</td></tr><tr><td style="border:none;" align="left">&#x027e8;<italic>I</italic>/&#x003c3;&#x027e9;</td><td style="border:none;" align="left">22.6&#x000a0;(3.5)</td><td style="border:none;" align="left">11.6&#x000a0;(2.3)</td><td style="border:none;" align="left">22.7&#x000a0;(2.6)</td><td style="border:none;" align="left">13.8&#x000a0;(2.4)</td><td style="border:none;" align="left">9.0&#x000a0;(3.0)</td></tr><tr><td style="border:none;" align="left"><italic>R</italic><sub>sym</sub><xref rid="t1fn1" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">0.029&#x000a0;(0.325)</td><td style="border:none;" align="left">0.051&#x000a0;(0.461)</td><td style="border:none;" align="left">0.045&#x000a0;(0.613)</td><td style="border:none;" align="left">0.038&#x000a0;(0.452)</td><td style="border:none;" align="left">0.068&#x000a0;(0.351)</td></tr><tr><td style="border:none;" align="left"><italic>R</italic><sub>crys</sub><xref rid="tbl1-fn2" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">0.215</td><td style="border:none;" align="left">0.213</td><td style="border:none;" align="left">0.177</td><td style="border:none;" align="left">0.230</td><td style="border:none;" align="left">0.192</td></tr><tr><td style="border:none;" align="left"><italic>R</italic><sub>free</sub><xref rid="tbl1-fn3" ref-type="table-fn">d</xref></td><td style="border:none;" align="left">0.253</td><td style="border:none;" align="left">0.251</td><td style="border:none;" align="left">0.214</td><td style="border:none;" align="left">0.268</td><td style="border:none;" align="left">0.211</td></tr><tr><td style="border:none;" align="left">no. of amino acids</td><td style="border:none;" align="left">179</td><td style="border:none;" align="left">180</td><td style="border:none;" align="left">90</td><td style="border:none;" align="left">179</td><td style="border:none;" align="left">181</td></tr><tr><td style="border:none;" align="left">no. of protein atoms</td><td style="border:none;" align="left">1445</td><td style="border:none;" align="left">1454</td><td style="border:none;" align="left">751</td><td style="border:none;" align="left">1446</td><td style="border:none;" align="left">1464</td></tr><tr><td style="border:none;" align="left">no. of hetero atoms</td><td style="border:none;" align="left">20</td><td style="border:none;" align="left">46</td><td style="border:none;" align="left">29</td><td style="border:none;" align="left">30</td><td style="border:none;" align="left">36</td></tr><tr><td style="border:none;" align="left">no. of waters</td><td style="border:none;" align="left">173</td><td style="border:none;" align="left">19</td><td style="border:none;" align="left">137</td><td style="border:none;" align="left">76</td><td style="border:none;" align="left">321</td></tr><tr><td style="border:none;" align="left">rmsd<xref rid="tbl1-fn1" ref-type="table-fn">e</xref> for bond lengths (&#x000c5;)</td><td style="border:none;" align="left">0.020</td><td style="border:none;" align="left">0.013</td><td style="border:none;" align="left">0.012</td><td style="border:none;" align="left">0.024</td><td style="border:none;" align="left">0.015</td></tr><tr><td style="border:none;" align="left">rmsd<xref rid="tbl1-fn1" ref-type="table-fn">e</xref> for
bond angles (deg)</td><td style="border:none;" align="left">1.056</td><td style="border:none;" align="left">1.304</td><td style="border:none;" align="left">1.231</td><td style="border:none;" align="left">1.372</td><td style="border:none;" align="left">1.133</td></tr><tr><td style="border:none;" align="left">mean <italic>B</italic> factor (&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">28.92</td><td style="border:none;" align="left">48.73</td><td style="border:none;" align="left">20.67</td><td style="border:none;" align="left">39.00</td><td style="border:none;" align="left">14.91</td></tr><tr><td style="border:none;" align="left">protein atoms (&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">27.69</td><td style="border:none;" align="left">48.00</td><td style="border:none;" align="left">18.61</td><td style="border:none;" align="left">38.74</td><td style="border:none;" align="left">13.62</td></tr><tr><td style="border:none;" align="left">hetero atoms
(&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">44.54</td><td style="border:none;" align="left">71.95</td><td style="border:none;" align="left">28.82</td><td style="border:none;" align="left">38.00</td><td style="border:none;" align="left">22.01</td></tr><tr><td style="border:none;" align="left">water atoms (&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">37.36</td><td style="border:none;" align="left">48.65</td><td style="border:none;" align="left">30.21</td><td style="border:none;" align="left">44.32</td><td style="border:none;" align="left">25.09</td></tr><tr><td style="border:none;" align="left">Ramachandran outliers (%)</td><td style="border:none;" align="left">0.0</td><td style="border:none;" align="left">0.0</td><td style="border:none;" align="left">0.0</td><td style="border:none;" align="left">0.0</td><td style="border:none;" align="left">0.0</td></tr><tr><td style="border:none;" align="left">Ramachandran favored (%)</td><td style="border:none;" align="left">100.0</td><td style="border:none;" align="left">98.9</td><td style="border:none;" align="left">100.0</td><td style="border:none;" align="left">98.9</td><td style="border:none;" align="left">99.4</td></tr></tbody></table><table-wrap-foot><fn id="t1fn88"><label>a</label><p>The numbers in
parentheses represent
values from the highest-resolution shell (1.66&#x02013;1.58 &#x000c5;
for SC124, 2.3&#x02013;2.18 &#x000c5; for SC1475, 1.74&#x02013;1.65 &#x000c5;
for SC1982, 1.82&#x02013;1.73 &#x000c5; for SBi4172, and 1.10&#x02013;1.08
&#x000c5; for SBi4434). Atom counts do not include H.</p></fn><fn id="t1fn1"><label>b</label><p><italic>R</italic><sub>sym</sub> = &#x02211;<sub><italic>h</italic></sub>(&#x02211;<sub><italic>j</italic></sub>|<italic>I</italic><sub><italic>hj</italic></sub> &#x02013;
&#x027e8;<italic>I</italic><sub><italic>h</italic></sub>&#x027e9;|/&#x02211;<italic>I</italic><sub><italic>h</italic>,<italic>j</italic></sub>), where <italic>h</italic> is the set of Miller indices, <italic>j</italic> is the
set of observations of reflection <italic>h</italic>, and &#x027e8;<italic>I</italic><sub><italic>h</italic></sub>&#x027e9; is the mean intensity.</p></fn><fn id="tbl1-fn2"><label>c</label><p><italic>R</italic><sub>crys</sub> = &#x02211;<sub><italic>h</italic></sub>||<italic>F</italic><sub>o,<italic>h</italic></sub>| &#x02013; |<italic>F</italic><sub>c,<italic>h</italic></sub>||/&#x02211;<sub><italic>h</italic></sub>|<italic>F</italic><sub>o,<italic>h</italic></sub>|.</p></fn><fn id="tbl1-fn3"><label>d</label><p><italic>R</italic><sub>free</sub> was calculated
using a percentage of the complete data set excluded
from refinement.</p></fn><fn id="tbl1-fn1"><label>e</label><p>Deviations
from ideal values.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.4.3"><title>Structure
Determination and Refinement</title><p>To determine
the structure of <sup>Ca</sup>S100B in complex with SBi<italic>X</italic>s, we performed molecular replacement (MR). A search model from a
previous S100B structure [Protein Data Bank (PDB) entry 1MHO(<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref>)] was generated by removing coordinates for ligands and water. Molecular
replacement was conducted within the AUTOMR<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> function of the PHENIX<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> software suite.
The models were finished by manual building within COOT.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> The models were refined by the PHENIX.REFINE<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> function of the PHENIX<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> software suite. Ligands and waters were incorporated into the models
by visual inspection of the |<italic>F</italic><sub>o</sub>| &#x02013;
|<italic>F</italic><sub>c</sub>| omit maps. The structure refinement
statistics are summarized in Table <xref rid="tbl1" ref-type="other">1</xref>.</p></sec></sec><sec id="sec2.5"><title>Cell-Based Assay with WM115 Malignant Melanoma Cells</title><p>The
malignant melanoma cell line, WM115, was obtained from American
Type Tissue Collection (ATCC) and cultured in minimum essential medium
(Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and 100 units/mL penicillin-streptomycin (PS). The cells were
infected with SMARTvector 2.0 lentiviral particles containing either
nontargeting scrambled or anti-S100B shRNA according to manufacturer&#x02019;s
recommendations (Thermo Scientific-Dharmacon). The following day,
the medium containing lentivirus was removed, the cells were washed
twice with PBS and trypsinized, and each well was expanded into a
24-well plate containing growth medium supplemented with puromycin
(0.5 &#x003bc;g/mL). Upon confluence, the wells were trypsinized and
single-cell diluted into 96-well plates. Positive clones with a reduction
in the level of S100B protein expression were maintained in puromycin-containing
medium.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup></p><p>A cellular screen was then
developed with these WM115 cell lines, and further test compounds
were shown to bind S100B <italic>in vitro</italic>. In this cellular
assay, the ability of SBi<italic>X</italic> molecules to inhibit the
growth of WM115 melanoma cells infected with shRNA lentivirus (Dharmacon)
targeting S100B (shRNA<sup>S100B</sup>, i.e., low S100B) or a scrambled
control (shRNA<sup>scrambled</sup>, i.e., high S100B) was examined
quantitatively. The methods used were similar to those used previously
and included the use of a Biomek FX Laboratory Automation Workstation
(Beckman-Coulter) equipped with a 96-channel pipetting head.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Specifically, 20 &#x003bc;L of MEM (Corning) supplemented
with 10% fetal bovine serum, 0.5 &#x003bc;g/mL puromycin, and 1% Pen/Strep
was added to each well of a 384-well, clear bottom, tissue culture
plate (Corning) containing 600 cells per well such that growing uninhibited
they reach 80% confluence in 5 days. After the cells had grown for
24 h at 37 &#x000b0;C in a 5% CO<sub>2</sub> humidity-controlled incubator,
20 &#x003bc;L of the compound was added directly to the cell culture
medium, while control cultures received an equivalent amount of DMSO.
After being incubated for an additional 4 days, the cells were lysed
by transferring 20 &#x003bc;L of lysis buffer consisting of 1.8% Igepal
with a 1:10000 dilution of SYBR Green I (10000&#x000d7;, Invitrogen)
to each well. The plates were then returned to the incubator for 24
h. The fluorescence intensity was then read through the bottom of
the plate using a PolarStar fluorescent plate reader (BMG) using 485
nm excitation and 520 nm emission filters. The SYBR Green fluorescence
is used to measure total DNA that in turn correlates with the cell
number as previously described.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> The EC<sub>50</sub> of each compound was determined using serial dilutions and
performed in a minimum of three replicates. Hill curves of each replicate
were generated using Origin Data Analysis Software.</p><p>To analyze
changes in total p53 protein levels upon treatment with
SC1982, WM115 cells were seeded in triplicate at a density of 70 &#x000d7;
10<sup>5</sup> cells in 60 mm dishes in 1&#x000d7; MEM (Cellgro) supplemented
with 10% FBS, 100 units/mL PS, and 0.5 &#x003bc;g/mL puromycin and allowed
to adhere overnight. The following day, the old medium was removed
and new medium containing 5 &#x003bc;M SC1982 or DMSO was added. The
cells were harvested 4 h post-treatment using cold 1&#x000d7; RIPA lysis
buffer [0.5 M Tris-HCl (pH 7.4), 1.5 M NaCl, 2.5% deoxycholic acid,
10% Igepal, and 10 mM EDTA] and subjected to Western blotting.</p><p>Western blotting was performed using 30 &#x003bc;g of cell lysates
loaded on a 12% sodium dodecyl sulfate&#x02013;polyacrylamide gel electrophoresis
gel (NuPage), which was subsequently transferred to PVDF membranes
(Millipore) and reacted with p53 mouse monoclonal antibody (DO-1,
Santa Cruz), mouse anti-S100B antibody (BD Biosciences), and mouse
anti-GAPDH antibody at dilutions recommended by the manufacturers.
The blots were then reacted with goat anti-mouse secondary antibodies
(Kirkegaard &#x00026; Perry Laboratories) and treated with Immobilon Western
Chemiluminescent HRP Substrate (Millipore) at dilutions recommended
by the manufacturer.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>The binding of <sup>Ca</sup>S100B to p53 downregulates tumor suppressor
activity in cancer cells such as malignant melanoma,<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> so a search for small molecule inhibitors that bind <sup>Ca</sup>S100B and prevent formation of the <sup>Ca</sup>S100B&#x02013;p53
complex was undertaken. A fluorescence polarization competition assay
(FPCA) was performed against the 1280-compound Library of Pharmacologically
Active Compounds (<italic>LOPAC1280</italic>). Because of the location
of Cys84 within the <sup>Ca</sup>S100B binding pocket (i.e., between
sites 1 and 3), the focus of this investigation was a series of covalent
complexes from this that were predicted to covalently bind at Cys84
of <sup>Ca</sup>S100B. SBi4172 is a structural analogue of the covalent
modifier SC0844<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> and was thought to bind
similarly. SC124, or disulfiram, is a known covalent modifier.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> The chemical nature of SBi4434 suggests the
possibility of adduct formation and is confirmed here. To gain additional
opportunities for characterization of covalent adducts, compounds
were also taken from a previously reported screen versus the 2000-compound
Spectrum Collection.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> The compounds characterized
in this study include SC1982 and SC1475, which were reported in the
previous study as being dependent on Cys84 for binding, but the formed
covalent adducts were not investigated.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Cellular and biophysical characterization of these covalently bound
inhibitors was explored, including their three-dimensional structures
when bound to <sup>Ca</sup>S100B (Tables <xref rid="tbl1" ref-type="other">1</xref>&#x02013;<xref rid="tbl4" ref-type="other">4</xref>).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Cellular Assays<xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th colspan="2" align="center">high
S100B EC<sub>50</sub> (&#x003bc;M)<hr/></th><th colspan="2" align="center">low
S100B EC<sub>50</sub> (&#x003bc;M)<hr/></th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th></tr><tr><th style="border:none;" align="center">compound</th><th style="border:none;" align="center">mean</th><th style="border:none;" align="center" char=".">SD</th><th style="border:none;" align="center">mean</th><th style="border:none;" align="center" char=".">SD</th><th style="border:none;" align="center" char="."><italic>T</italic>-test</th><th style="border:none;" align="center" char=".">ratio (&#x02213;)</th><th style="border:none;" align="center" char="."><italic>n</italic></th></tr></thead><tbody><tr><td style="border:none;" align="left">SC124</td><td style="border:none;" align="left">0.06</td><td style="border:none;" align="char" char=".">0.06</td><td style="border:none;" align="left">0.23</td><td style="border:none;" align="char" char=".">0.38</td><td style="border:none;" align="char" char=".">0.321</td><td style="border:none;" align="char" char=".">3.57</td><td style="border:none;" align="char" char=".">6</td></tr><tr><td style="border:none;" align="left">SC1475</td><td style="border:none;" align="left">13.87</td><td style="border:none;" align="char" char=".">1.70</td><td style="border:none;" align="left">13.81</td><td style="border:none;" align="char" char=".">5.00</td><td style="border:none;" align="char" char=".">0.980</td><td style="border:none;" align="char" char=".">1.00</td><td style="border:none;" align="char" char=".">6</td></tr><tr><td style="border:none;" align="left">SC1982</td><td style="border:none;" align="left">5.05</td><td style="border:none;" align="char" char=".">1.13</td><td style="border:none;" align="left">8.95</td><td style="border:none;" align="char" char=".">2.68</td><td style="border:none;" align="char" char=".">0.001</td><td style="border:none;" align="char" char=".">1.77</td><td style="border:none;" align="char" char=".">8</td></tr><tr><td style="border:none;" align="left">SBi4172</td><td style="border:none;" align="left">2.07</td><td style="border:none;" align="char" char=".">1.29</td><td style="border:none;" align="left">3.11</td><td style="border:none;" align="char" char=".">1.43</td><td style="border:none;" align="char" char=".">0.127</td><td style="border:none;" align="char" char=".">1.50</td><td style="border:none;" align="char" char=".">9</td></tr><tr><td style="border:none;" align="left">SBi4434</td><td style="border:none;" align="left">FI</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">FI</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Assays used WM115
melanoma cells
transfected with shRNA<sup>scrambled</sup> (i.e., high S100B) or shRNA<sup>S100B</sup> (i.e., low S100B).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Calculated rmsd&#x02019;s (angstroms)
of Models from C<sup>&#x003b1;</sup> Atoms of 1MHO<xref rid="t3fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/></colgroup><tbody><tr><td style="border:none;" align="left"><sup>Ca</sup>S100B&#x02013;SC124</td><td style="border:none;" align="char" char=".">0.382&#x000a0;(0.381)</td><td style="border:none;" align="char" char=".">0.435&#x000a0;(0.328)</td></tr><tr><td style="border:none;" align="left"><sup>Ca</sup>S100B&#x02013;SC1475</td><td style="border:none;" align="char" char=".">0.329&#x000a0;(0.258)</td><td style="border:none;" align="char" char=".">0.325(0.256)</td></tr><tr><td style="border:none;" align="left"><sup>Ca</sup>S100B&#x02013;SC1982</td><td style="border:none;" align="char" char=".">0.391&#x000a0;(0.279)</td><td style="border:none;" align="char" char=".">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><sup>Ca</sup>S100B&#x02013;SBi4172</td><td style="border:none;" align="char" char=".">0.518&#x000a0;(0.378)</td><td style="border:none;" align="char" char=".">0.546&#x000a0;(0.382)</td></tr><tr><td style="border:none;" align="left"><sup>Ca</sup>S100B&#x02013;SBi4434</td><td style="border:none;" align="char" char=".">0.310&#x000a0;(0.279)</td><td style="border:none;" align="char" char=".">0.319&#x000a0;(0.252)</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>One or both modeled protein chains
(when applicable) are compared to the single-protein chain within 1MHO. Numbers in parentheses
are the calculated rmsd&#x02019;s of only globally conserved residues
1&#x02013;84.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Measured Distortions of the Zinc Binding
Site<xref rid="t4fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char=".">His15</th><th style="border:none;" align="center">His25</th><th style="border:none;" align="center">His85</th><th style="border:none;" align="center">Glu89</th></tr></thead><tbody><tr><td style="border:none;" align="left">SC1982</td><td style="border:none;" align="char" char=".">95.5&#x000b0;</td><td style="border:none;" align="left">19.1&#x000b0;</td><td style="border:none;" align="left">0.7&#x000a0;&#x000c5;</td><td style="border:none;" align="left">1.9&#x000a0;&#x000c5;</td></tr><tr><td style="border:none;" align="left">SBi4172</td><td style="border:none;" align="char" char=".">76.9&#x000b0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">1.4&#x000a0;&#x000c5;</td><td style="border:none;" align="left">2.5&#x000a0;&#x000c5;</td></tr><tr><td style="border:none;" align="left">SBi4434</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">28.1&#x000b0;</td><td style="border:none;" align="left">67.9&#x000b0;</td><td style="border:none;" align="left">1.5&#x000a0;&#x000c5;</td></tr><tr><td style="border:none;" align="left">SC1475</td><td style="border:none;" align="char" char=".">68.2&#x000b0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">0.8&#x000a0;&#x000c5;</td><td style="border:none;" align="left">1.3&#x000a0;&#x000c5;</td></tr><tr><td style="border:none;" align="left">SC124</td><td style="border:none;" align="char" char=".">82.9&#x000b0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">1.0&#x000a0;&#x000c5;</td><td style="border:none;" align="left">1.6&#x000a0;&#x000c5;</td></tr><tr><td style="border:none;" align="left">SC0844<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></td><td style="border:none;" align="char" char=".">38.3&#x000b0;</td><td style="border:none;" align="left">2.8&#x000a0;&#x000c5;</td><td style="border:none;" align="left">157.7&#x000b0;</td><td style="border:none;" align="left">5.0&#x000a0;&#x000c5;</td></tr><tr><td style="border:none;" align="left">SC0322<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></td><td style="border:none;" align="char" char=".">31.2&#x000b0;</td><td style="border:none;" align="left">31.7&#x000b0;</td><td style="border:none;" align="left">49.1&#x000b0;</td><td style="border:none;" align="left">not applicable</td></tr></tbody></table><table-wrap-foot><fn id="t4fn1"><label>a</label><p>Shown are averaged movements of
side chains in angstroms (directional movement of C<sup>&#x003b3;</sup>) or degrees (swing of C<sup>&#x003b2;</sup>&#x02013;C<sup>&#x003b3;</sup>). As Glu89 was not modeled in 1MHO, directional measurements are from the
carbonyl carbon atom of Phe88.</p></fn></table-wrap-foot></table-wrap><sec id="sec3.1"><title>NMR Studies</title><p>Backbone resonance assignments were completed
for each SBi<italic>X</italic>&#x02013;S100B complex using standard
multidimensional heteronuclear NMR data, and the chemical shift perturbations
in <sup>Ca</sup>S100B (with or without the compound) were evaluated
as described for other S100B inhibitors.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref33">33</xref>&#x02212;<xref ref-type="bibr" rid="ref36">36</xref></sup> In general, the SBi<italic>X</italic> complexes studied here showed
the largest perturbations within a well-defined binding pocket of <sup>Ca</sup>S100B comprising helices 3 and 4 and loop 2 (termed the &#x0201c;hinge&#x0201d;
region). These observations are consistent with the FPCA, which identified
SBi<italic>X</italic>s that compete with TRTK12 peptide binding.</p><sec id="sec3.1.1"><title>Chemical
Shift Assignments</title><p>Titrations of compound into <sup>Ca</sup>S100B were monitored using <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC
NMR experiments, as previously described.<sup><xref ref-type="bibr" rid="ref32">32</xref>&#x02212;<xref ref-type="bibr" rid="ref34">34</xref></sup> Because perturbations
were not always easily tracked during the titration, a series of HNCA,
HNCOCA, <sup>15</sup>N-edited NOESY-HSQC, and <sup>15</sup>N-HNH (HMQC-NOESY-HSQC)
NMR experiments were collected at the end of each titration to unambiguously
assign all the chemical shift values in the compound-bound state.
The reaction products for five small molecules (SC124, SC1475, SC1982,
SBi4172, and SBi4434) bound to <sup>Ca</sup>S100B were assessed by
monitoring perturbations of backbone <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC correlations after the compounds were added and fully reacted
(Figure <xref rid="fig2" ref-type="fig">2</xref> and Figures S1&#x02013;S5 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Assigned two-dimensional <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC
NMR spectra. The binding of five small molecules (SC124, SC1475, SC1982,
SBi4172, and SBi4434) to <sup>Ca</sup>S100B was assessed by monitoring
perturbations of backbone <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC
NMR experiments. Chemical shift perturbations in NMR spectra for <sup>Ca</sup>S100B in the presence of SBi4172 could not be measured as
the compound caused <sup>Ca</sup>S100B to from soluble aggregates.
The solid horizontal line is plotted at the mean perturbation (in
hertz) plus one standard deviation for each data set.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0001" id="gr2" position="float"/></fig><p>In the presence of SC124, many of the <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC correlations of <sup>Ca</sup>S100B were
perturbed,
with the most significant perturbations (&#x02265;mean &#x000b1; SD) occurring
for residues in loop 2 (His42) and helix 4 (Ser78, Thr81, Thr82, Ala83,
Glu86, Phe87, and His90). Likewise, several other residues in loop
2 (Phe43, Leu44, Glu45, and Glu46) and helix 4 (Cys84, His85, and
Glu89) either broadened and/or disappeared upon addition of SC124.</p><p>Similarly, residues in loop 2 and helix 4 were perturbed for modifications
via SC1982 (loop 2, His42 and Leu44; helix 4, Ser78, Thr82, Ala83,
Cys84, His85, Glu86, and Glu89) and SBi4434 (loop 2, Ser41, His42,
and Phe43; helix 4, Thr81, Thr82, Ala83, Cys84, His85, and Glu86).
For SC1475, changes in loop 2 (His42 and Lys48), helix 4 (Val80, Thr81,
Thr82, and His85), and helix 1 (Met7) were found in solution. These
data are all consistent with the notion that SC124, SC1475, and SC1982
all react with Cys84 because loop 2 and helix 4 are in the proximity
of each other in the crystallographic structures of <sup>Ca</sup>S100B
and have been previously described to facilitate the binding of small
molecules. For SBi4172, the chemical shift perturbations during the
reaction could not be measured because the compound induced aggregation
of <sup>Ca</sup>S100B (Figure S4 of the <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>). To further characterize the structural impact
of covalent modifications at Cys84 on <sup>Ca</sup>S100B, we next
determined the structures of the S100B complexes with each compound
by X-ray crystallography.</p></sec></sec><sec id="sec3.2"><title>Crystallographic Studies</title><sec id="sec3.2.1"><title>Covalent
Modifications at Cys84 Affect Target Binding of <sup>Ca</sup>S100B</title><p>The structures of <sup>Ca</sup>S100B&#x02013;inhibitor
complexes (SC124, SC1475, SC1982, SBi4172, and SBi4434) are compared,
each of which was confirmed to have the SBi<italic>X</italic> molecule
covalently bound to Cys84 of <sup>Ca</sup>S100B (Figure <xref rid="fig3" ref-type="fig">3</xref>). In all five of these structural models, each <sup>Ca</sup>S100B subunit consists of four helices (helix 1, E2&#x02013;G19; helix
2, K28&#x02013;L40; helix 3, E49&#x02013;D61; helix 4, D69&#x02013;F88),
two small antiparallel &#x003b2;-strands, and a Ca<sup>2+</sup> ion
bound to both the typical and noncanonical EF-hand calcium binding
domains. Likewise, the typical EF-hand is in the &#x0201c;open&#x0201d;
Ca<sup>2+</sup>-bound conformation, as is generally found in <sup>Ca</sup>S100B structures,<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> and the dimer
interface is aligned as a symmetric X-type four-helix bundle comprising
helices 1, 1&#x02032;, 4, and 4&#x02032;.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref34">34</xref>&#x02212;<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref47">47</xref></sup> Comparison of these five structures
to that of <sup>Ca</sup>S100B (PDB entry 1MHO(<xref ref-type="bibr" rid="ref47">47</xref>)) with no
drug target reveals a strong conservation of the global fold (Table <xref rid="tbl3" ref-type="other">3</xref>); however, deviations in the positions of several
side chains in the target binding site of <sup>Ca</sup>S100B were
observed, as necessary, to accommodate the binding of various SBi<italic>X</italic> molecules. These include residues in helix 4 and/or loop
4 and in helix 1 (i.e., His15) in some cases, as described below (i.e.,
for the <sup>Ca</sup>S100B&#x02013;SC124 complex). The specifics of
each structure also provide details of potential synthetic strategies
for engineering a single molecule that occupies all three persistent
&#x0201c;pockets&#x0201d; within the S100B target binding site, so the
individual structures and specific structural changes will be discussed
in some detail.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Chemical modification of Cys84 of <sup>Ca</sup>S100B.
Shown are
schematics that provide an overview of the chemical modification of
Cys84 by compounds (A) SC124, (B) SC1475, (C) SC1982, (D) SBi4172,
and (E) SBi4434.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0002" id="gr3" position="float"/></fig></sec><sec id="sec3.2.2"><title><sup>Ca</sup>S100B&#x02013;SC124</title><p>The X-ray structure
of a product resulting from mixing SC124 (disulfiram) with Ca<sup>2+</sup>-bound S100B (<sup>Ca</sup>S100B&#x02013;SC124) was determined
at 1.58 &#x000c5; resolution (Figure <xref rid="fig4" ref-type="fig">4</xref>). The asymmetric
unit included two <sup>Ca</sup>S100B subunits (chains A and B) forming
the biologically active form of dimeric <sup>Ca</sup>S100B. Residues
Met0&#x02013;Phe88 and Met0&#x02013;Glu89 were modeled in chains A and
B, respectively. In the final refined model (<italic>R</italic><sub>crys</sub> and <italic>R</italic><sub>free</sub> values of 0.215
and 0.253, respectively), all residues were in the favored (100%)
regions of the Ramachandran plot with no outliers (Table <xref rid="tbl1" ref-type="other">1</xref>). Each subunit of <sup>Ca</sup>S100B&#x02013;SC124
was found to coordinate two calcium ions as is typical of S100 proteins,<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> and electron density was also clearly observed
in the target binding sites for each subunit of <sup>Ca</sup>S100B
as a result of nucleophilic attack of Cys84 by SC124 (Figures <xref rid="fig3" ref-type="fig">3</xref> and <xref rid="fig4" ref-type="fig">4</xref>). The structure of
the bound product was also consistent with what has been found previously
with other protein adducts involving SC124<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> (Figure <xref rid="fig3" ref-type="fig">3</xref>). Interestingly, though, the Cys84-bound
SC124 adduct has somewhat different positions in each subunit of <sup>Ca</sup>S100B, and this was the first indication that this region,
termed site 2, of <sup>Ca</sup>S100B can accommodate various orientations
for small inhibitors. Curiously, the binding of SC124 causes the side
chain of Glu89 in one subunit to occupy a pocket that can tightly
coordinate a Zn<sup>2+</sup> ion,<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref56">56</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> and as a result, His15 is reoriented. Note, in Zn<sup>2+</sup>-bound structures of <sup>Ca</sup>S100B described elsewhere,<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref56">56</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> Zn<sup>2+</sup> is coordinated
by residues His15, His25, His85, and Glu89.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Crystallographic structure
of the <sup>Ca</sup>S100B&#x02013;SC124
complex. (A) Shown is an |<italic>F</italic><sub>o</sub>| &#x02013;
|<italic>F</italic><sub>c</sub>| electron density omit map of SC124
covalently bound to Cys84 of <sup>Ca</sup>S100B with the map contoured
at the 2.5&#x003c3; level. (B) Dimeric <sup>Ca</sup>S100B is rendered
in a surface diagram with residues within 4 &#x000c5; of the SC124 colored
yellow. SC124 is found within persistent binding site 2. (C) SC124
is situated within the hydrophobic pocket formed by Val8, Phe43, Phe87,
and Phe88. SC124 makes no hydrogen bonds. The neighboring Zn<sup>2+</sup> binding site composed of Glu89, His15, His25, and His85 is also
rendered.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0003" id="gr4" position="float"/></fig></sec><sec id="sec3.2.3"><title>S100B&#x02013;SC1475</title><p>The X-ray structure of a product
resulting from mixing SC1475 (3,4-dimethoxydalbergione) with Ca<sup>2+</sup>-bound S100B (<sup>Ca</sup>S100B&#x02013;SC1475) was determined
at 2.18 &#x000c5; resolution (Figure <xref rid="fig5" ref-type="fig">5</xref>). The asymmetric
unit included two <sup>Ca</sup>S100B subunits (chains X and A) of <sup>Ca</sup>S100B, and in both chains, residues Met0&#x02013;Glu89 were
modeled into the electron density. In the final refined structure
(<italic>R</italic><sub>crys</sub> and <italic>R</italic><sub>free</sub> values of 0.213 and 0.251, respectively), all residues were in the
most favored (98.9%) or allowed (1.1%) regions of the Ramachandran
plot with no outliers (see Table <xref rid="tbl1" ref-type="other">1</xref>). In each
subunit, two Ca<sup>2+</sup> ions, one SC1475 molecule, and 19 waters
were resolved from the calculated electron density of the <sup>Ca</sup>S100B&#x02013;SC1475 structure. It was also clear that SC1475 covalently
modified <sup>Ca</sup>S100B via nucleophilic substitution of Cys84
into the benzoquinone moiety of the drug. Such a reaction is not uncommon,
has been observed in toxic metabolites of acetaminophen, and results
in the tautomerization of the moiety (Figure <xref rid="fig3" ref-type="fig">3</xref>), as previously found.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> Upon inspection,
no hydrogen bonds were observed from residues of <sup>Ca</sup>S100B
to SC1475, but the small molecule was situated in a hydrophobic pocket
defined by residues in loop 2, termed the &#x0201c;hinge region&#x0201d;
of S100B (Phe43) and helix 4 (Ile80, Ala83, Phe87, and Phe88). Specifically,
the hydroquinone moiety of SC1475 stacks with Phe43, and the alkene
moiety aligns favorably with the aromatic ring of Phe87. His15 is
observed to swing outward from the Zn<sup>2+</sup> binding site as
observed in other <sup>Ca</sup>S100B&#x02013;SBi<italic>X</italic> structures,
and unlike <sup>Ca</sup>S100B complexes of SBi4172, SC124, and SC1982,
Glu89 does not invade the Zn<sup>2+</sup> binding site (<italic>vide
infra</italic>).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Crystallographic structure of the <sup>Ca</sup>S100B&#x02013;SC1475
complex. (A) Shown is an |<italic>F</italic><sub>o</sub>| &#x02013;
|<italic>F</italic><sub>c</sub>| electron density omit map of SC1475
covalently bound to Cys84 of <sup>Ca</sup>S100B with the map contoured
at the 2.5&#x003c3; level. (B) Dimeric <sup>Ca</sup>S100B is rendered
in a surface diagram with residues within 4 &#x000c5; of the SC1475 colored
yellow. SC1475 is found within persistent binding site 2. (C) SC1475
is situated within the hydrophobic pocket formed by Phe43, Leu44,
Ile80, Ala83, Phe87, and Phe88. SC1475 makes no hydrogen bonds. The
neighboring Zn<sup>2+</sup> binding site composed of Glu89, His15,
His25, and His85 is also rendered.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0004" id="gr5" position="float"/></fig></sec><sec id="sec3.2.4"><title><sup>Ca</sup>S100B&#x02013;SC1982</title><p>The X-ray structure
of <sup>Ca</sup>S100B bound to SC1982 (Rubescensin A; <sup>Ca</sup>S100B&#x02013;SC1982) was determined at 1.65 &#x000c5; resolution (Figure <xref rid="fig6" ref-type="fig">6</xref>). The asymmetric unit contained one <sup>Ca</sup>S100B subunit, and density for Met0&#x02013;Glu91 could be readily
modeled with the second subunit mapped on the basis of its location
within the crystal symmetry. In the final refined model (<italic>R</italic><sub>crys</sub> and <italic>R</italic><sub>free</sub> values of 0.177
and 0.214, respectively), all residues were in the highly favored
(100%) region of the Ramachandran plot with no outliers (Table <xref rid="tbl1" ref-type="other">1</xref>). Each subunit of <sup>Ca</sup>S100B&#x02013;SC1982
was found to coordinate two Ca<sup>2+</sup> ions (one in each EF-hand),
and one SC1982 molecule occupied each of the target protein binding
sites via covalent modification (in the region termed site 2). Specifically,
the alkene of SC1982 is reduced via Michael addition from the thiol
of Cys84 from <sup>Ca</sup>S100B<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> (Figure <xref rid="fig3" ref-type="fig">3</xref>). After covalent attachment, SC1982 makes two hydrogen
bonds to the backbone carbonyls of loop 2 (His42 and Phe43) and forms
several hydrophobic interactions with residues in the target binding
pocket of <sup>Ca</sup>S100B, including those in loop 2 (Phe43) and
helix 4 (Ile80, Phe87, and Phe88). His15 is once again observed to
move outward from the Zn<sup>2+</sup> binding site, and like the structures
of <sup>Ca</sup>S100B&#x02013;SC124 and <sup>Ca</sup>S100B&#x02013;SBi4172,
the covalent binding of SC1982 causes the side chain of Glu89 to intrude
into a region of the protein, which can bind Zn<sup>2+</sup>, and
causes the side chain of His15 to rotate away fairly drastically.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Crystallographic
structure of the <sup>Ca</sup>S100B&#x02013;SC1982
complex. (A) Shown is an |<italic>F</italic><sub>o</sub>| &#x02013;
|<italic>F</italic><sub>c</sub>| electron density omit map of SC1982
covalently bound to Cys84 of <sup>Ca</sup>S100B with the map contoured
at the 2.5&#x003c3; level. (B) Dimeric <sup>Ca</sup>S100B is rendered
in a surface diagram with residues within 4 &#x000c5; of the SC1982 colored
yellow. SC1982 is found within persistent binding site 2. (C) SC1982
is situated within the hydrophobic pocket formed by Phe43, Ala83,
Phe87, and Phe88. SC1982 makes hydrogen bonds to the backbone carbonyls
of His42 and Phe43. The neighboring Zn<sup>2+</sup> binding site composed
of Glu89, His15, His25, and His85 is also rendered.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0005" id="gr6" position="float"/></fig><p>Electron density for a highly coordinated atom
that is too dense
to be water was identified. As calcium is prevalent in the system
and because of the identity of the contributors in the coordination
(Asp63, Asp69, and six water molecules), a third calcium ion was modeled
into this density (confirmed by anomalous difference maps).</p></sec><sec id="sec3.2.5"><title><sup>Ca</sup>S100B&#x02013;SBi4172</title><p>The X-ray structure
of chelerythrine-bound <sup>Ca</sup>S100B, <sup>Ca</sup>S100B&#x02013;SBi4172,
was determined at 1.73 &#x000c5; resolution (Figure <xref rid="fig7" ref-type="fig">7</xref>). The asymmetric unit in the drug complex included two S100B
subunits (chains A and B) forming the biologically active dimeric
form of <sup>Ca</sup>S100B. In chain A, residues Met0&#x02013;Glu89
were modeled into the electron density, and in chain B, only Ser1&#x02013;Glu89
could be resolved. Each subunit of the <sup>Ca</sup>S100B&#x02013;SBi4172
complex coordinated two Ca<sup>2+</sup> ions; however, only one molecule
of SBi4172 could be observed and was located in the model for chain
B. Sparse density was observed in the analogous binding pocket of
chain A, but it was not sufficiently well defined for accurate modeling
of the SBi4172 inhibitor. A more detailed analysis of chain A showed
that a lack of density in the second subunit likely occurred as a
result of spatial restraints imposed by the crystal packing. In the
final refined model (<italic>R</italic><sub>crys</sub> and <italic>R</italic><sub>free</sub> values of 0.230 and 0.268, respectively),
all residues in both subunits were in the favored (98.9%) or allowed
regions (1.1%) of the Ramachandran plot with no outliers (Table <xref rid="tbl1" ref-type="other">1</xref>). As clearly defined by the calculated electron
density maps, SBi4172 was found to react with Cys84 via hydration
of a double bond of SBi4172<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> (Figure <xref rid="fig3" ref-type="fig">3</xref>). Once SBi4172 was covalently bound, a dioxole
oxygen atom of SBi4172 was found to make water-bridged interactions
with the backbone carbonyl of Phe43. Otherwise, SBi4172 was situated
in a hydrophobic pocket composed of side chains within loop 2 (Phe43),
helix 4 (Ile80, Ala83, Phe87, and Phe88), and helix 1&#x02032; (Val7,
Val8, and Ile11). Like the earlier inhibitor-bound <sup>Ca</sup>S100B
complexes, the side chain moiety of His15 was found to move out of
the established Zn<sup>2+</sup> binding site of <sup>Ca</sup>S100B.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Crystallographic
structure of the <sup>Ca</sup>S100B&#x02013;SBi4172
complex. (A) Shown is an |<italic>F</italic><sub>o</sub>| &#x02013;
|<italic>F</italic><sub>c</sub>| electron density omit map of SBi4172
covalently bound to Cys84 of <sup>Ca</sup>S100B with the map contoured
at the 2.5&#x003c3; level. (B) Dimeric <sup>Ca</sup>S100B is rendered
in a surface diagram with residues within 4 &#x000c5; of the SBi4172
colored yellow. SBi4172 is found within persistent binding site 2.
(C) SBi4172 is situated within the hydrophobic pocket formed by Phe43,
Phe87, and Phe88. SBi4172 makes a water-bridged interaction with the
backbone carbonyl of Phe43. The neighboring Zn<sup>2+</sup> binding
site composed of Glu89, His15, His25, and His85 is also rendered.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0006" id="gr7" position="float"/></fig></sec><sec id="sec3.2.6"><title><sup>Ca</sup>S100B&#x02013;SBi4434</title><p>The X-ray structure
of SBi4434 {2,3-bis[(2-hydroxyethyl)thio]-1,4-naphthoquinone} bound
to <sup>Ca</sup>S100B (<sup>Ca</sup>S100B&#x02013;SBi4434) was determined
at 1.08 &#x000c5; resolution (Figure <xref rid="fig8" ref-type="fig">8</xref>). The asymmetric
unit included two S100B subunits (chains A and X) forming the biologically
active dimeric form of S100B. In chain A, residues Met0&#x02013;Glu91were
modeled while only residues Met0&#x02013;Phe88 of chain X could be
resolved. Each subunit in the <sup>Ca</sup>S100B&#x02013;SBi4434 structure
bound two calcium ions and a SBi4434 molecule. In the final refined
model (<italic>R</italic><sub>crys</sub> and <italic>R</italic><sub>free</sub> values of 0.192 and 0.211, respectively), all residues
were in the favored (99.4%) or allowed regions (0.6%) of the Ramachandran
plot with no outliers <bold>(</bold>Table <xref rid="tbl1" ref-type="other">1</xref>). Sole among the structures described here, the high resolution
of the diffraction data produced by the <sup>Ca</sup>S100B&#x02013;SBi4434
crystal allowed for the inclusion of riding hydrogen atoms in this
particular model. As clearly defined by the calculated electron density
maps, SBi4434 covalently modifies <sup>Ca</sup>S100B at Cys84. As
seen, the thiol of Cys84 substitutes for one of the thioglycol moieties
of SBi4434 (Figure <xref rid="fig3" ref-type="fig">3</xref>). The second thioglycol
moiety is allowed much conformational flexibility as evidenced by
the sparse electron density for these atoms as well as the alternative
conformations of the moiety modeled in the two inhibitor molecules.
The compound does not make any hydrogen bonds with the protein but
is nestled in a hydrophobic pocket formed by loop 2 and helix 4 with
the aromatic rings of SBi4434 stacked between the side chains of Phe43
and Phe87. In this model, His85 swings out of the Zn<sup>2+</sup> binding
site.</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>Crystallographic structure of the <sup>Ca</sup>S100B&#x02013;SBi4434
complex. (A) Shown is an |<italic>F</italic><sub>o</sub>| &#x02013;
|<italic>F</italic><sub>c</sub>| electron density omit map of SBi4434
covalently bound to Cys84 of <sup>Ca</sup>S100B with the map contoured
at the 2.5&#x003c3; level. (B) Dimeric <sup>Ca</sup>S100B is rendered
in a surface diagram with residues within 4 &#x000c5; of the SBi4434
colored yellow. SBi4434 is found within persistent binding site 2.
(C) SBi4434 is situated within the hydrophobic pocket formed by Phe43,
Phe87, and Phe88. SBi4434 makes no hydrogen bonds. The neighboring
Zn<sup>2+</sup> binding site composed of Glu89, His15, His25, and
His85 is also rendered.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0007" id="gr8" position="float"/></fig><p>Coordinates and structure factors have been deposited in
the Protein
Data Bank as entries 4PE1 for <sup>Ca</sup>S100B&#x02013;SC124, 4PE4 for <sup>Ca</sup>S100B&#x02013;SC1475, 4PE7 for <sup>Ca</sup>S100B&#x02013;SC1982, 4PDZ for <sup>Ca</sup>S100B&#x02013;SBi4172, and 4PE0 for <sup>Ca</sup>S100B&#x02013;SBi4434.</p></sec></sec><sec id="sec3.3"><title>Cell-Based Assay</title><p>To determine whether
covalent modification
of Cys84 affects cell proliferation in malignant melanoma, its effect
on the growth of WM115 malignant melanoma cells, which express elevated
levels of the S100B protein, was measured as described previously.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Briefly, proliferation of WM115 cells stably
transfected with either shRNA<sup>scrambled</sup> (i.e., high S100B)
or shRNA<sup>S100B</sup> (i.e., low S100B) was evaluated in triplicate
following a 4 day incubation in the absence or presence of each compound
at varying concentrations (Table <xref rid="tbl2" ref-type="other">2</xref>). For each
titration, knockdown of the S100B protein was confirmed by Western
blot analysis (3-fold decrease; <italic>n</italic> = 4) (Figure <xref rid="fig9" ref-type="fig">9</xref>), and EC<sub>50</sub> values were determined using
the average of three or more titrations. With SC1475 as an exception
(ratio of 1.00), it was found that lower concentrations of SC124,
SC1982, and SBi4172 were needed to inhibit cell growth with the shRNA<sup>scrambled</sup> versus the shRNA<sup>S100B</sup> knockdown WM115
cells (1.50 &#x0003c; ratio &#x0003c; 3.57). This is consistent with the compounds
having specificity toward S100B-containing cells; however, only titrations
with SC1982 were shown to be S100B-selective (1.77-fold) with a statistically
significant <italic>t</italic>-test (<italic>p</italic> = 0.001; <italic>n</italic> = 8). Consistent with this result, p53 levels were 2-fold
higher (<italic>n</italic> = 4) in the presence than in the absence
of SC1982 (in Figure <xref rid="fig9" ref-type="fig">9</xref>, compare lanes 1 and
3 and lanes 2 and 4, respectively). This result along with an observation
of S100B expression-dependent growth inhibition suggests that SC1982
displays an on-target effect of S100B inhibition with subsequent p53
restoration. The last compound, SBi4434, showed fluorescence interference
with the SYBR Green dye, so it was excluded from further evaluation.</p><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Westen
blot analysis. The control without drug was treated with
the same DMSO concentration (0.01%). The addition of SC1982 did not
affect the protein levels of S100B in the shRNA<sup>scrambled</sup> or shRNA<sup>S100B</sup> cell lines. However, both shRNA<sup>scrambled</sup> and shRNA<sup>S100B</sup> cell lines had a measurable gain in total
p53 protein levels in the presence of SC1982. This result along with
an observation of S100B expression-dependent growth inhibition suggests
that SC1982 displays an on-target effect of S100B inhibition with
subsequent p53 restoration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0008" id="gr9" position="float"/></fig></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Malignant melanoma is the fifth and seventh
most common cancer
among men and women,<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> respectively, so
the discovery of novel therapeutics for its treatment remains a high
priority. Elevated S100B is a prognostic indicator for assessing disease
progression, disease recurrence, and metastatic potential in patients
with MM.<sup><xref ref-type="bibr" rid="ref62">62</xref>&#x02212;<xref ref-type="bibr" rid="ref68">68</xref></sup> It is also established that S100B not only is a clinical marker
but also binds to and negatively regulates p53 at the protein level.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> While the p53 tumor suppressor protein is mutated in many human
cancers,<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> it is typically wild-type (wt,
&#x0003e;90%) in MM,<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> so restoring p53 protein by inhibiting
S100B represents a novel therapeutic strategy for treating MM. While
low-molecular weight compounds that block the p53 binding site on
S100B and inhibit formation of the S100B&#x02013;p53 complex exist,
improving their affinity, efficacy, and specificity remains a priority.
Thus, S100B represents a new cancer target, and improved SBi<italic>X</italic>s should provide novel therapeutic(s) for treating MM by
restoring active p53 protein.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup></p><p>Structure&#x02013;function
characterizations of five novel inhibitors
of the <sup>Ca</sup>S100B&#x02013;p53 interaction are presented here.
Of the five compounds, SC1982 has the most significant hydrogen bonding
network within the <sup>Ca</sup>S100B binding pocket, and interestingly,
it demonstrated the highest level of target specific activity in the
WM115 cellular assay. Note that despite the relatively low EC<sub>50</sub> of SC124, expectations should be tempered when considering
this compound. SC124 is small with a scaffold lacking complexity.
It forms no hydrogen bonds with the target protein and lacks even
a consistent binding pose within the two monomers of S100B. These
details leave little potential for SC124 as a therapeutic that would
not be sequestered elsewhere within the cell, and unsurprisingly,
it lacks statistically significant S100B expression-dependent growth
inhibition.</p><p>Such target specific effects are important when
considering the
relationship between off-target effects and toxicity. This is particularly
important when considering the therapeutic application of covalent
modifiers because their off-target effects are not uncommon and are
often severe. One successful example of a drug linked to the protein
via Michael addition is Afatinib, which is used in the treatment of
metastatic non-small cell lung carcinoma (NSCLC).<sup><xref ref-type="bibr" rid="ref70">70</xref>,<xref ref-type="bibr" rid="ref71">71</xref></sup> The target specific effect of SC1982 (Figure <xref rid="fig9" ref-type="fig">9</xref> and Table <xref rid="tbl2" ref-type="other">2</xref>) is reassuring and warrants further
investigation as a chemical scaffold for engineering novel SBi<italic>X</italic> molecules. In fact, SC1982 and each compound presented
here offer a new chemical scaffold for continued SAR studies for improving
affinity and specificity.</p><p>These structures can be used for guiding
the design of new inhibitors
using multiple approaches. The most straightforward of these is via
&#x0201c;tethering&#x0201d; new functional moieties onto the existing
covalently bound compound(s) and keeping the covalent bond in place.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> A second strategy is to develop quickly reversible
covalent modifications, as described previously,<sup><xref ref-type="bibr" rid="ref73">73</xref></sup> for the inclusion of an &#x003b1;-cyanoacrylamide functionality.
This modification increases the intrinsic reactivity of an olefin
and eliminates the formation of irreversible adducts. Such an approach
could enhance the bioavailability and selectivity of the inhibitory
compound. For Cys84 of <sup>Ca</sup>S100B, such a cyanoacrylamide
(or cyanoacrylate) would react with cysteine thiols under physiological
conditions in an energetically favorable manner and become rapidly
reversible, including having off rates on the subsecond to second
time scales.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> In this situation, the level
of off-site targeting is significantly reduced, and the covalent nature
of the adduct for the target of interest is long-lived, as needed
for therapeutic efficacy.</p><p>A third approach to obtaining high-affinity,
high-specificity S100B
inhibitors with these data is to engineer compounds that make use
of all three persistent pockets in the p53 binding site. In this regard,
the inhibitors presented here are particularly important because they
are located within the persistent binding pocket termed &#x0201c;site
2&#x0201d;. Therefore, regardless of whether these inhibitors are covalently
bound, they provide exquisite detail for how to connect chemical moieties
in sites 1 and 3. Therefore, the inhibitors presented here can be
considered in combination with chemical functionalities described
in previous structural studies of other SBi<italic>X</italic>s<sup><xref ref-type="bibr" rid="ref33">33</xref>&#x02212;<xref ref-type="bibr" rid="ref36">36</xref></sup> to produce a ligand capable of binding all three persistent binding
sites simultaneously. The simultaneous occupation of sites 1 and 2
will be of interest first because &#x0201c;site 3&#x0201d; binders within <sup>Ca</sup>S100B have been thoroughly described elsewhere.</p><p>Although
the mechanisms involved in adduct formation may differ
between compounds, SC124, SC1475, SC1982, SBi4172, and SBi4434 (as
well as for SC0844 and SC322<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> studied
previously), together these compounds comprise a subset of S100B inhibitors
that impact the conformational state of <sup>Ca</sup>S100B in a similar
manner. In particular, an adduct added to Cys84 clashes with side
chains on helix 4 and thereby rotates a Zn<sup>2+</sup> binding residue,
Glu89, into a new location. As a result, residues comprising the Zn<sup>2+</sup> binding site (His15, His25, His85, and Glu89) are subsequently
reordered. Although the particulars of this effect on the Zn<sup>2+</sup> binding site may be unique to an individual compound and may or
may not have an effect on S100B activities, the covalent modifier
family of SBi<italic>X</italic>s described here is &#x0201c;hallmarked&#x0201d;
by this common structural perturbation (Figure <xref rid="fig10" ref-type="fig">10</xref>). Table <xref rid="tbl4" ref-type="other">4</xref> lists the effect through measurements
of directional movements of atoms and torsions of residue side chains.
The most disruptive feature of this conformational change is an intrusion
of Glu89 into the Zn<sup>2+</sup> site with a subsequent exit of one
of the localized histidine side chains. Further investigation may
prove this to be a meaningful observation because the oxidation of
Cys84 has functional implications with regard to the regulation of
S100B by redox.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> The inhibitory properties
of these compounds may in part be attributed to the manipulation of
this natural regulatory Zn<sup>2+</sup> binding feature of S100B and
are very likely functionally important.</p><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Distortion of the zinc
binding site is a hallmark of the S100B
covalent inhibitor family. Shown are ribbon diagrams of <sup>Ca</sup>S100B in the presence (yellow) and absence (gray) of a covalent modifier
(SC1982) with residues and ligands of interest shown as sticks. The
covalent modifier family of SBi<italic>X</italic>s is hallmarked by
perturbation in the conformational state of the residues forming the
Zn<sup>2+</sup> binding site (His15, His25, His85, and Glu89). Commonly,
Glu89 is seen intruding on the Zn<sup>2+</sup> with a subsequent displacement
of a histidine side chain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-005552_0009" id="gr10" position="float"/></fig><p>Although we have demonstrated a restoration in p53 levels
alongside
the inhibition of S100B, it must be noted that within WM115 malignant
melanoma cells, S100B has been associated with factors other than
p53. For instance, S100B was found to enhance cell viability and modulate
MAPK signaling by binding directly to the p90 ribosomal S6 kinase
(RSK). The formation of this complex blocks ERK-dependent phosphorylation
of RSK and sequesters RSK into the cytosol, preventing it from acting
on nuclear targets. Thus, S100B has been shown to increase the level
of cell survival in malignant melanoma by contributing to abnormal
ERK/RSK signaling.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup>Also, a target of S100B
is the receptor for advanced glycation end products (RAGE). RAGE is
upregulated in late metastatic stages of samples from melanoma patients.
The overexpression of RAGE is associated with mesenchymal-like morphologies
in WM115 cells and results in greater migration abilities and reduced
proliferation properties. This supports a role of RAGE in the metastatic
switch of melanoma cells. Interestingly, overexpression of RAGE results
in the increased level of expression of S100B and lower levels of
p53, ERK1/2, cyclin E, and NF-&#x003ba;B.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup></p></sec></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>Figures
S1&#x02013;S5 show overlaid
two-dimensional <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC spectra of <sup>Ca</sup>S100B and <sup>Ca</sup>S100B&#x02013;SBi<italic>X</italic> complexes. This material is available free of charge via the Internet
at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi5005552_si_001.pdf"><caption><p>bi5005552_si_001.pdf</p></caption></media></supplementary-material></sec><notes id="notes-1" notes-type="funding-statement"><p>This
work was
supported by grants from the National Institutes of Health (NIH) (GM58888
and CA107331) to D.J.W. The training of M.C.C. is supported by an
NIH T32 grant (CA154274). Work performed at synchrotron facilities
was supported by NIH Grants P41GM103403 (D.B.N., NE-CAT) and P41GM103393
(SSRL).</p></notes><notes id="NOTES-d1139e2763-autogenerated" notes-type="conflict-of-interest"><p>The
authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>Research conducted at the Advanced
Photon Source on the Northeastern
Collaborative Access Team beamlines is supported by the National Institutes
of Health, National Institute of General Medical Sciences. Use of
the Advanced Photon Source, an Office of Science User Facility operated
for the U.S. Department of Energy (DOE) Office of Science by Argonne
National Laboratory, was supported by the U.S. DOE. Use of the Stanford
Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory,
is supported by the U.S. DOE, Office of Science and Office of Basic
Energy. The SSRL Structural Molecular Biology Program is supported
by the DOE Office of Biological and Environmental Research and by
the National Institutes of Health, National Institute of General Medical
Sciences.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>MM</term><def><p>malignant melanoma</p></def></def-item><def-item><term>SBi<italic>X</italic></term><def><p>S100B inhibitor
where <italic>X</italic> is a number</p></def></def-item><def-item><term><sup>Ca</sup>S100B</term><def><p>calcium-bound S100B</p></def></def-item><def-item><term>NMR</term><def><p>nuclear magnetic resonance</p></def></def-item><def-item><term>HSQC</term><def><p>heteronuclear
single-quantum coherence</p></def></def-item><def-item><term>rmsd</term><def><p>root-mean-square deviation</p></def></def-item><def-item><term>SD</term><def><p>standard deviation.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Kwong</surname><given-names>L. N.</given-names></name>; <name><surname>Davies</surname><given-names>M. A.</given-names></name> (<year>2014</year>) <article-title>Targeted therapy for melanoma: Rational combinatorial
approaches</article-title>. <source>Oncogene</source>
<volume>33</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23416974</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Topalian</surname><given-names>S. L.</given-names></name>; <name><surname>Hodi</surname><given-names>F. S.</given-names></name>; <name><surname>Brahmer</surname><given-names>J. R.</given-names></name>; <name><surname>Gettinger</surname><given-names>S. N.</given-names></name>; <name><surname>Smith</surname><given-names>D. C.</given-names></name>; <name><surname>McDermott</surname><given-names>D. F.</given-names></name>; <name><surname>Powderly</surname><given-names>J. D.</given-names></name>; <name><surname>Carvajal</surname><given-names>R. D.</given-names></name>; <name><surname>Sosman</surname><given-names>J. A.</given-names></name>; <name><surname>Atkins</surname><given-names>M. B.</given-names></name>; <name><surname>Leming</surname><given-names>P. D.</given-names></name>; <name><surname>Spigel</surname><given-names>D. R.</given-names></name>; <name><surname>Antonia</surname><given-names>S. J.</given-names></name>; <name><surname>Horn</surname><given-names>L.</given-names></name>; <name><surname>Drake</surname><given-names>C. G.</given-names></name>; <name><surname>Pardoll</surname><given-names>D. M.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Sharfman</surname><given-names>W. H.</given-names></name>; <name><surname>Anders</surname><given-names>R. A.</given-names></name>; <name><surname>Taube</surname><given-names>J. M.</given-names></name>; <name><surname>McMiller</surname><given-names>T. L.</given-names></name>; <name><surname>Xu</surname><given-names>H.</given-names></name>; <name><surname>Korman</surname><given-names>A. J.</given-names></name>; <name><surname>Jure-Kunkel</surname><given-names>M.</given-names></name>; <name><surname>Agrawal</surname><given-names>S.</given-names></name>; <name><surname>McDonald</surname><given-names>D.</given-names></name>; <name><surname>Kollia</surname><given-names>G. D.</given-names></name>; <name><surname>Gupta</surname><given-names>A.</given-names></name>; <name><surname>Wigginton</surname><given-names>J. M.</given-names></name>; <name><surname>Sznol</surname><given-names>M.</given-names></name> (<year>2012</year>) <article-title>Safety, activity, and immune correlates
of anti-PD-1 antibody in cancer</article-title>. <source>N. Engl. J.
Med.</source>
<volume>366</volume>, <fpage>2443</fpage>&#x02013;<lpage>2454</lpage>.<pub-id pub-id-type="pmid">22658127</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Bollag</surname><given-names>G.</given-names></name>; <name><surname>Hirth</surname><given-names>P.</given-names></name>; <name><surname>Tsai</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Ibrahim</surname><given-names>P. N.</given-names></name>; <name><surname>Cho</surname><given-names>H.</given-names></name>; <name><surname>Spevak</surname><given-names>W.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Habets</surname><given-names>G.</given-names></name>; <name><surname>Burton</surname><given-names>E. A.</given-names></name>; <name><surname>Wong</surname><given-names>B.</given-names></name>; <name><surname>Tsang</surname><given-names>G.</given-names></name>; <name><surname>West</surname><given-names>B. L.</given-names></name>; <name><surname>Powell</surname><given-names>B.</given-names></name>; <name><surname>Shellooe</surname><given-names>R.</given-names></name>; <name><surname>Marimuthu</surname><given-names>A.</given-names></name>; <name><surname>Nguyen</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>K. Y.</given-names></name>; <name><surname>Artis</surname><given-names>D. R.</given-names></name>; <name><surname>Schlessinger</surname><given-names>J.</given-names></name>; <name><surname>Su</surname><given-names>F.</given-names></name>; <name><surname>Higgins</surname><given-names>B.</given-names></name>; <name><surname>Iyer</surname><given-names>R.</given-names></name>; <name><surname>D&#x02019;Andrea</surname><given-names>K.</given-names></name>; <name><surname>Koehler</surname><given-names>A.</given-names></name>; <name><surname>Stumm</surname><given-names>M.</given-names></name>; <name><surname>Lin</surname><given-names>P. S.</given-names></name>; <name><surname>Lee</surname><given-names>R. J.</given-names></name>; <name><surname>Grippo</surname><given-names>J.</given-names></name>; <name><surname>Puzanov</surname><given-names>I.</given-names></name>; <name><surname>Kim</surname><given-names>K. B.</given-names></name>; <name><surname>Ribas</surname><given-names>A.</given-names></name>; <name><surname>McArthur</surname><given-names>G. A.</given-names></name>; <name><surname>Sosman</surname><given-names>J. A.</given-names></name>; <name><surname>Chapman</surname><given-names>P. B.</given-names></name>; <name><surname>Flaherty</surname><given-names>K. T.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name>; <name><surname>Nathanson</surname><given-names>K. L.</given-names></name>; <name><surname>Nolop</surname><given-names>K.</given-names></name> (<year>2010</year>) <article-title>Clinical efficacy of a RAF inhibitor
needs broad target blockade in BRAF-mutant melanoma</article-title>. <source>Nature</source>
<volume>467</volume>, <fpage>596</fpage>&#x02013;<lpage>599</lpage>.<pub-id pub-id-type="pmid">20823850</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Flaherty</surname><given-names>K. T.</given-names></name>; <name><surname>Puzanov</surname><given-names>I.</given-names></name>; <name><surname>Kim</surname><given-names>K. B.</given-names></name>; <name><surname>Ribas</surname><given-names>A.</given-names></name>; <name><surname>McArthur</surname><given-names>G. A.</given-names></name>; <name><surname>Sosman</surname><given-names>J. A.</given-names></name>; <name><surname>O&#x02019;Dwyer</surname><given-names>P. J.</given-names></name>; <name><surname>Lee</surname><given-names>R. J.</given-names></name>; <name><surname>Grippo</surname><given-names>J. F.</given-names></name>; <name><surname>Nolop</surname><given-names>K.</given-names></name>; <name><surname>Chapman</surname><given-names>P. B.</given-names></name> (<year>2010</year>) <article-title>Inhibition of mutated, activated
BRAF in metastatic melanoma</article-title>. <source>N. Engl. J. Med.</source>
<volume>363</volume>, <fpage>809</fpage>&#x02013;<lpage>819</lpage>.<pub-id pub-id-type="pmid">20818844</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Espinosa</surname><given-names>E.</given-names></name>; <name><surname>Grob</surname><given-names>J. J.</given-names></name>; <name><surname>Dummer</surname><given-names>R.</given-names></name>; <name><surname>Rutkowski</surname><given-names>P.</given-names></name>; <name><surname>Robert</surname><given-names>C.</given-names></name>; <name><surname>Gogas</surname><given-names>H.</given-names></name>; <name><surname>Kefford</surname><given-names>R.</given-names></name>; <name><surname>Eggermont</surname><given-names>A. M.</given-names></name>; <name><surname>Martin Algarra</surname><given-names>S.</given-names></name>; <name><surname>Hauschild</surname><given-names>A.</given-names></name>; <name><surname>Schadendorf</surname><given-names>D.</given-names></name> (<year>2014</year>) <article-title>Treatment
Algorithms in Stage IV Melanoma</article-title>. <source>American Journal
of Therapeutics</source>
<fpage>DOI: 10.1097/MJT.0b013e31829e885c</fpage>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Gogas</surname><given-names>H.</given-names></name>; <name><surname>Abali</surname><given-names>H.</given-names></name>; <name><surname>Ascierto</surname><given-names>P. A.</given-names></name>; <name><surname>Demidov</surname><given-names>L.</given-names></name>; <name><surname>Pehamberger</surname><given-names>H.</given-names></name>; <name><surname>Robert</surname><given-names>C.</given-names></name>; <name><surname>Schachter</surname><given-names>J.</given-names></name>; <name><surname>Eggermont</surname><given-names>A. M.</given-names></name>; <name><surname>Hauschild</surname><given-names>A.</given-names></name>; <name><surname>Espinosa</surname><given-names>E.</given-names></name> (<year>2013</year>) <article-title>Who Benefits Most From
Adjuvant Interferon
Treatment for Melanoma?</article-title>. <source>American Journal of
Therapeutics</source>
<fpage>DOI: 10.1097/MJT.0b013e31829e883d</fpage>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Jang</surname><given-names>S.</given-names></name>; <name><surname>Atkins</surname><given-names>M. B.</given-names></name> (<year>2013</year>) <article-title>Which drug, and
when, for patients with BRAF-mutant
melanoma?</article-title>. <source>Lancet Oncol.</source>
<volume>14</volume>, <fpage>e60</fpage>&#x02013;<lpage>e69</lpage>.<pub-id pub-id-type="pmid">23369684</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Marcus</surname><given-names>D. M.</given-names></name>; <name><surname>Lowe</surname><given-names>M.</given-names></name>; <name><surname>Khan</surname><given-names>M. K.</given-names></name>; <name><surname>Lawson</surname><given-names>D. H.</given-names></name>; <name><surname>Crocker</surname><given-names>I. R.</given-names></name>; <name><surname>Shelton</surname><given-names>J. W.</given-names></name>; <name><surname>Melton</surname><given-names>A.</given-names></name>; <name><surname>Maynard</surname><given-names>N.</given-names></name>; <name><surname>Delman</surname><given-names>K. A.</given-names></name>; <name><surname>Carlson</surname><given-names>G. W.</given-names></name>; <name><surname>Rizzo</surname><given-names>M.</given-names></name> (<year>2013</year>) <article-title>Prognostic Factors
for Overall Survival
After Radiosurgery for Brain Metastases From Melanoma</article-title>. <source>Am. J. Clin. Oncol.</source>
<fpage>DOI: 10.1097/COC.0b013e318280d7be</fpage>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Kashani-Sabet</surname><given-names>M.</given-names></name> (<year>2014</year>) <article-title>Molecular
markers in melanoma</article-title>. <source>Br. J. Dermatol.</source>
<volume>170</volume>, <fpage>31</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">23815339</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Riechers</surname><given-names>A.</given-names></name>; <name><surname>Bosserhoff</surname><given-names>A. K.</given-names></name> (<year>2014</year>) <article-title>Melanoma
inhibitory activity in melanoma diagnostics
and therapy: A small protein is looming large</article-title>. <source>Exp. Dermatol.</source>
<volume>23</volume>, <fpage>12</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">24372647</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>El
Hajj</surname><given-names>P.</given-names></name>; <name><surname>Journe</surname><given-names>F.</given-names></name>; <name><surname>Wiedig</surname><given-names>M.</given-names></name>; <name><surname>Laios</surname><given-names>I.</given-names></name>; <name><surname>Sales</surname><given-names>F.</given-names></name>; <name><surname>Galibert</surname><given-names>M. D.</given-names></name>; <name><surname>Van Kempen</surname><given-names>L. C.</given-names></name>; <name><surname>Spatz</surname><given-names>A.</given-names></name>; <name><surname>Badran</surname><given-names>B.</given-names></name>; <name><surname>Larsimont</surname><given-names>D.</given-names></name>; <name><surname>Awada</surname><given-names>A.</given-names></name>; <name><surname>Ghanem</surname><given-names>G.</given-names></name> (<year>2013</year>) <article-title>Tyrosinase-related
protein 1 mRNA expression in lymph node metastases predicts overall
survival in high-risk melanoma patients</article-title>. <source>Br.
J. Cancer</source>
<volume>108</volume>, <fpage>1641</fpage>&#x02013;<lpage>1647</lpage>.<pub-id pub-id-type="pmid">23519055</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Henry</surname><given-names>L.</given-names></name>; <name><surname>Fabre</surname><given-names>C.</given-names></name>; <name><surname>Guiraud</surname><given-names>I.</given-names></name>; <name><surname>Bastide</surname><given-names>S.</given-names></name>; <name><surname>Fabbro-Peray</surname><given-names>P.</given-names></name>; <name><surname>Martinez</surname><given-names>J.</given-names></name>; <name><surname>Lavabre-Bertrand</surname><given-names>T.</given-names></name>; <name><surname>Meunier</surname><given-names>L.</given-names></name>; <name><surname>Stoebner</surname><given-names>P. E.</given-names></name> (<year>2013</year>) <article-title>Clinical
use of p-proteasome in discriminating metastatic melanoma patients:
Comparative study with LDH, MIA and S100B protein</article-title>. <source>Int. J. Cancer</source>
<volume>133</volume>, <fpage>142</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">23238767</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Wieder</surname><given-names>H. A.</given-names></name>; <name><surname>Tekin</surname><given-names>G.</given-names></name>; <name><surname>Rosenbaum-Krumme</surname><given-names>S.</given-names></name>; <name><surname>Klode</surname><given-names>J.</given-names></name>; <name><surname>Altenbernd</surname><given-names>J.</given-names></name>; <name><surname>Bockisch</surname><given-names>A.</given-names></name>; <name><surname>Nagarajah</surname><given-names>J.</given-names></name> (<year>2013</year>) <article-title>18FDG-PET to assess recurrence and
long term survival in patients with malignant melanoma</article-title>. <source>Nuklearmedizin</source>
<volume>52</volume>, <fpage>198</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">23969722</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Schiltz</surname><given-names>P. M.</given-names></name>; <name><surname>Dillman</surname><given-names>R. O.</given-names></name>; <name><surname>Korse</surname><given-names>C. M.</given-names></name>; <name><surname>Cubellis</surname><given-names>J. M.</given-names></name>; <name><surname>Lee</surname><given-names>G. J.</given-names></name>; <name><surname>De Gast</surname><given-names>G. C.</given-names></name> (<year>2008</year>) <article-title>Lack of elevation of serum S100B in patients with metastatic
melanoma as a predictor of outcome after induction with an autologous
vaccine of proliferating tumor cells and dendritic cells</article-title>. <source>Cancer Biother. Radiopharm.</source>
<volume>23</volume>, <fpage>214</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">18454690</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>O&#x02019;Rourke</surname><given-names>M. G.</given-names></name>; <name><surname>Johnson</surname><given-names>M.</given-names></name>; <name><surname>Lanagan</surname><given-names>C.</given-names></name>; <name><surname>See</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Bell</surname><given-names>J. R.</given-names></name>; <name><surname>Slater</surname><given-names>G. J.</given-names></name>; <name><surname>Kerr</surname><given-names>B. M.</given-names></name>; <name><surname>Crowe</surname><given-names>B.</given-names></name>; <name><surname>Purdie</surname><given-names>D. M.</given-names></name>; <name><surname>Elliott</surname><given-names>S. L.</given-names></name>; <name><surname>Ellem</surname><given-names>K. A.</given-names></name>; <name><surname>Schmidt</surname><given-names>C. W.</given-names></name> (<year>2003</year>) <article-title>Durable
complete clinical responses in a phase I/II trial using an autologous
melanoma cell/dendritic cell vaccine</article-title>. <source>Cancer
Immunol. Immunother.</source>
<volume>52</volume>, <fpage>387</fpage>&#x02013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">12682787</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Hartman</surname><given-names>K. G.</given-names></name>; <name><surname>McKnight</surname><given-names>L. E.</given-names></name>; <name><surname>Liriano</surname><given-names>M. A.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2013</year>) <article-title>The evolution of
S100B inhibitors for the treatment of malignant melanoma</article-title>. <source>Future Med. Chem.</source>
<volume>5</volume>, <fpage>97</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">23256816</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>Q.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Carrier</surname><given-names>F.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2010</year>) <article-title>The calcium-binding
protein S100B down-regulates p53 and apoptosis in malignant melanoma</article-title>. <source>J. Biol. Chem.</source>
<volume>285</volume>, <fpage>27487</fpage>&#x02013;<lpage>27498</lpage>.<pub-id pub-id-type="pmid">20587415</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>Q.</given-names></name>; <name><surname>Yan</surname><given-names>Z.</given-names></name>; <name><surname>Markowitz</surname><given-names>J.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Carrier</surname><given-names>F.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2004</year>) <article-title>Inhibiting S100B
restores p53 levels in primary malignant melanoma cancer cells</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>34071</fpage>&#x02013;<lpage>34077</lpage>.<pub-id pub-id-type="pmid">15178678</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Baudier</surname><given-names>J.</given-names></name>; <name><surname>Delphin</surname><given-names>C.</given-names></name>; <name><surname>Grunwald</surname><given-names>D.</given-names></name>; <name><surname>Khochbin</surname><given-names>S.</given-names></name>; <name><surname>Lawrence</surname><given-names>J. J.</given-names></name> (<year>1992</year>) <article-title>Characterization
of the tumor suppressor protein p53 as a protein kinase C substrate
and a S100b-binding protein</article-title>. <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
<volume>89</volume>, <fpage>11627</fpage>&#x02013;<lpage>11631</lpage>.<pub-id pub-id-type="pmid">1454855</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Rustandi</surname><given-names>R.
R.</given-names></name>; <name><surname>Baldisseri</surname><given-names>D. M.</given-names></name>; <name><surname>Drohat</surname><given-names>A. C.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>1999</year>) <article-title>Structural changes
in the C-terminus of Ca<sup>2+</sup>-bound rat S100B (&#x003b2;&#x003b2;)
upon binding to a peptide derived from the C-terminal regulatory domain
of p53</article-title>. <source>Protein Sci.</source>
<volume>8</volume>, <fpage>1743</fpage>&#x02013;<lpage>1751</lpage>.<pub-id pub-id-type="pmid">10493575</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Rustandi</surname><given-names>R. R.</given-names></name>; <name><surname>Baldisseri</surname><given-names>D. M.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2000</year>) <article-title>Structure of the
negative regulatory
domain of p53 bound to S100B(&#x003b2;&#x003b2;)</article-title>. <source>Nat. Struct. Biol.</source>
<volume>7</volume>, <fpage>570</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">10876243</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Rustandi</surname><given-names>R. R.</given-names></name>; <name><surname>Drohat</surname><given-names>A. C.</given-names></name>; <name><surname>Baldisseri</surname><given-names>D. M.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>1998</year>) <article-title>The Ca<sup>2+</sup>-dependent interaction of S100B(&#x003b2;&#x003b2;) with a peptide
derived from p53</article-title>. <source>Biochemistry</source>
<volume>37</volume>, <fpage>1951</fpage>&#x02013;<lpage>1960</lpage>.<pub-id pub-id-type="pmid">9485322</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Rustandi</surname><given-names>R. R.</given-names></name>; <name><surname>Drohat</surname><given-names>A. C.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>1998</year>) <article-title>S100B(&#x003b2;&#x003b2;)
inhibits the protein kinase C-dependent phosphorylation of a peptide
derived from p53 in a Ca<sup>2+</sup>-dependent manner</article-title>. <source>Protein Sci.</source>
<volume>7</volume>, <fpage>794</fpage>&#x02013;<lpage>798</lpage>.<pub-id pub-id-type="pmid">9541413</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Blake</surname><given-names>M.</given-names></name>; <name><surname>Tang</surname><given-names>C.</given-names></name>; <name><surname>Zimmer</surname><given-names>D.</given-names></name>; <name><surname>Rustandi</surname><given-names>R. R.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name>; <name><surname>Carrier</surname><given-names>F.</given-names></name> (<year>2001</year>) <article-title>Inhibition of p53 transcriptional
activity by the S100B calcium-binding protein</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>35037</fpage>&#x02013;<lpage>35041</lpage>.<pub-id pub-id-type="pmid">11454863</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="book" id="cit25"><person-group person-group-type="allauthors"><name><surname>Weber</surname><given-names>D. J.</given-names></name>, <name><surname>Rustandi</surname><given-names>R. R.</given-names></name>, <name><surname>Carrier</surname><given-names>F.</given-names></name>, and <name><surname>Zimmer</surname><given-names>D. B.</given-names></name></person-group> (<year>2000</year>) <article-title>Interaction of dimeric S100B(&#x003b2;&#x003b2;) with the tumor suppressor
protein: A model for Ca-dependent S100-target protein interactions</article-title>. In <source>The molecular basis of calcium action in biology and
medicine</source> (<person-group person-group-type="editor"><name><surname>Pochet</surname><given-names>R.</given-names></name></person-group>, Ed.) pp <fpage>469</fpage>&#x02013;<lpage>487</lpage>, <publisher-name>Kluwer Academic Publishers</publisher-name>, <publisher-loc>Dordrecht,
The Netherlands</publisher-loc>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Hussein</surname><given-names>M. R.</given-names></name>; <name><surname>Haemel</surname><given-names>A. K.</given-names></name>; <name><surname>Wood</surname><given-names>G. S.</given-names></name> (<year>2003</year>) <article-title>p53-related pathways and the molecular
pathogenesis of melanoma</article-title>. <source>Eur. J. Cancer Prev.</source>
<volume>12</volume>, <fpage>93</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">12671532</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Brown</surname><given-names>C. J.</given-names></name>; <name><surname>Lain</surname><given-names>S.</given-names></name>; <name><surname>Verma</surname><given-names>C. S.</given-names></name>; <name><surname>Fersht</surname><given-names>A. R.</given-names></name>; <name><surname>Lane</surname><given-names>D. P.</given-names></name> (<year>2009</year>) <article-title>Awakening
guardian angels: Drugging the p53 pathway</article-title>. <source>Nat.
Rev. Cancer</source>
<volume>9</volume>, <fpage>862</fpage>&#x02013;<lpage>873</lpage>.<pub-id pub-id-type="pmid">19935675</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Smith</surname><given-names>J.</given-names></name>; <name><surname>Stewart</surname><given-names>B. J.</given-names></name>; <name><surname>Glaysher</surname><given-names>S.</given-names></name>; <name><surname>Peregrin</surname><given-names>K.</given-names></name>; <name><surname>Knight</surname><given-names>L. A.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name>; <name><surname>Cree</surname><given-names>I. A.</given-names></name> (<year>2010</year>) <article-title>The effect
of pentamidine on melanoma
ex vivo</article-title>. <source>Anticancer Drugs</source>
<volume>21</volume>, <fpage>181</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">19966562</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Zimmer</surname><given-names>D. B.</given-names></name>; <name><surname>Lapidus</surname><given-names>R. G.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2013</year>) <article-title>In vivo screening
of S100B inhibitors
for melanoma therapy</article-title>. <source>Methods Mol. Biol.</source>
<volume>963</volume>, <fpage>303</fpage>&#x02013;<lpage>317</lpage>.<pub-id pub-id-type="pmid">23296618</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Jochemsen</surname><given-names>A. G.</given-names></name> (<year>2014</year>) <article-title>Reactivation
of p53 as therapeutic intervention for malignant melanoma</article-title>. <source>Curr. Opin. Oncol.</source>
<volume>26</volume>, <fpage>114</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">24275854</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Markowitz</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>I.</given-names></name>; <name><surname>Gitti</surname><given-names>R.</given-names></name>; <name><surname>Baldisseri</surname><given-names>D. M.</given-names></name>; <name><surname>Pan</surname><given-names>Y.</given-names></name>; <name><surname>Udan</surname><given-names>R.</given-names></name>; <name><surname>Carrier</surname><given-names>F.</given-names></name>; <name><surname>MacKerell</surname><given-names>A. D.</given-names><suffix>Jr.</suffix></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2004</year>) <article-title>Identification and characterization
of small molecule inhibitors of the calcium-dependent S100B-p53 tumor
suppressor interaction</article-title>. <source>J. Med. Chem.</source>
<volume>47</volume>, <fpage>5085</fpage>&#x02013;<lpage>5093</lpage>.<pub-id pub-id-type="pmid">15456252</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Charpentier</surname><given-names>T. H.</given-names></name>; <name><surname>Thompson</surname><given-names>L. E.</given-names></name>; <name><surname>Liriano</surname><given-names>M. A.</given-names></name>; <name><surname>Varney</surname><given-names>K. M.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Pozharski</surname><given-names>E.</given-names></name>; <name><surname>Toth</surname><given-names>E. A.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2010</year>) <article-title>The effects of CapZ
peptide (TRTK-12) binding to S100B-Ca<sup>2+</sup> as examined by
NMR and X-ray crystallography</article-title>. <source>J. Mol. Biol.</source>
<volume>396</volume>, <fpage>1227</fpage>&#x02013;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">20053360</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Charpentier</surname><given-names>T. H.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Liriano</surname><given-names>M. A.</given-names></name>; <name><surname>Varney</surname><given-names>K. M.</given-names></name>; <name><surname>Zhong</surname><given-names>S.</given-names></name>; <name><surname>Coop</surname><given-names>A.</given-names></name>; <name><surname>Pozharski</surname><given-names>E.</given-names></name>; <name><surname>MacKerell</surname><given-names>A. D.</given-names><suffix>Jr.</suffix></name>; <name><surname>Toth</surname><given-names>E. A.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2009</year>) <article-title>Small molecules
bound to unique sites in the target protein binding cleft of calcium-bound
S100B as characterized by nuclear magnetic resonance and X-ray crystallography</article-title>. <source>Biochemistry</source>
<volume>48</volume>, <fpage>6202</fpage>&#x02013;<lpage>6212</lpage>.<pub-id pub-id-type="pmid">19469484</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>McKnight</surname><given-names>L. E.</given-names></name>; <name><surname>Raman</surname><given-names>E. P.</given-names></name>; <name><surname>Bezawada</surname><given-names>P.</given-names></name>; <name><surname>Kudrimoti</surname><given-names>S.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Hartman</surname><given-names>K. G.</given-names></name>; <name><surname>Godoy-Ruiz</surname><given-names>R.</given-names></name>; <name><surname>Toth</surname><given-names>E. A.</given-names></name>; <name><surname>Coop</surname><given-names>A.</given-names></name>; <name><surname>Mackerell</surname><given-names>A. D.</given-names><suffix>Jr.</suffix></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2012</year>) <article-title>Structure-Based Discovery of a Novel
Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B</article-title>. <source>ACS Med. Chem. Lett.</source>
<volume>3</volume>, <fpage>975</fpage>&#x02013;<lpage>979</lpage>.<pub-id pub-id-type="pmid">23264854</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Charpentier</surname><given-names>T. H.</given-names></name>; <name><surname>Liriano</surname><given-names>M. A.</given-names></name>; <name><surname>Gianni</surname><given-names>K.</given-names></name>; <name><surname>Varney</surname><given-names>K. M.</given-names></name>; <name><surname>Pozharski</surname><given-names>E.</given-names></name>; <name><surname>Coop</surname><given-names>A.</given-names></name>; <name><surname>Toth</surname><given-names>E. A.</given-names></name>; <name><surname>Mackerell</surname><given-names>A. D.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2010</year>) <article-title>In vitro screening and structural characterization
of inhibitors of the S100B-p53 interaction</article-title>. <source>Int. J. High Throughput Screening</source>
<volume>2010</volume>, <fpage>109</fpage>&#x02013;<lpage>126</lpage>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Charpentier</surname><given-names>T. H.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Liriano</surname><given-names>M. A.</given-names></name>; <name><surname>Varney</surname><given-names>K. M.</given-names></name>; <name><surname>Pozharski</surname><given-names>E.</given-names></name>; <name><surname>MacKerell</surname><given-names>A. D.</given-names><suffix>Jr.</suffix></name>; <name><surname>Coop</surname><given-names>A.</given-names></name>; <name><surname>Toth</surname><given-names>E. A.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2008</year>) <article-title>Divalent metal ion complexes of S100B in the absence
and presence of pentamidine</article-title>. <source>J. Mol. Biol.</source>
<volume>382</volume>, <fpage>56</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">18602402</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Drohat</surname><given-names>A. C.</given-names></name>; <name><surname>Amburgey</surname><given-names>J. C.</given-names></name>; <name><surname>Abildgaard</surname><given-names>F.</given-names></name>; <name><surname>Starich</surname><given-names>M. R.</given-names></name>; <name><surname>Baldisseri</surname><given-names>D.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>1996</year>) <article-title>Solution structure
of rat apo-S100B(&#x003b2;&#x003b2;)
as determined by NMR spectroscopy</article-title>. <source>Biochemistry</source>
<volume>35</volume>, <fpage>11577</fpage>&#x02013;<lpage>11588</lpage>.<pub-id pub-id-type="pmid">8794737</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Amburgey</surname><given-names>J. C.</given-names></name>; <name><surname>Abildgaard</surname><given-names>F.</given-names></name>; <name><surname>Starich</surname><given-names>M. R.</given-names></name>; <name><surname>Shah</surname><given-names>S.</given-names></name>; <name><surname>Hilt</surname><given-names>D. C.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>1995</year>) <article-title><sup>1</sup>H, <sup>13</sup>C and <sup>15</sup>N NMR
assignments and solution secondary structure of rat Apo-S100&#x003b2;</article-title>. <source>J. Biomol. NMR</source>
<volume>6</volume>, <fpage>171</fpage>&#x02013;<lpage>179</lpage>.<pub-id pub-id-type="pmid">8589606</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Kabsch</surname><given-names>W.</given-names></name> (<year>2010</year>) <article-title>Xds</article-title>. <source>Acta Crystallogr.</source>
<volume>D66</volume>, <fpage>125</fpage>&#x02013;<lpage>132</lpage>.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Soltis</surname><given-names>S. M.</given-names></name>; <name><surname>Cohen</surname><given-names>A. E.</given-names></name>; <name><surname>Deacon</surname><given-names>A.</given-names></name>; <name><surname>Eriksson</surname><given-names>T.</given-names></name>; <name><surname>Gonzalez</surname><given-names>A.</given-names></name>; <name><surname>McPhillips</surname><given-names>S.</given-names></name>; <name><surname>Chui</surname><given-names>H.</given-names></name>; <name><surname>Dunten</surname><given-names>P.</given-names></name>; <name><surname>Hollenbeck</surname><given-names>M.</given-names></name>; <name><surname>Mathews</surname><given-names>I.</given-names></name>; <name><surname>Miller</surname><given-names>M.</given-names></name>; <name><surname>Moorhead</surname><given-names>P.</given-names></name>; <name><surname>Phizackerley</surname><given-names>R. P.</given-names></name>; <name><surname>Smith</surname><given-names>C.</given-names></name>; <name><surname>Song</surname><given-names>J.</given-names></name>; <name><surname>van dem Bedem</surname><given-names>H.</given-names></name>; <name><surname>Ellis</surname><given-names>P.</given-names></name>; <name><surname>Kuhn</surname><given-names>P.</given-names></name>; <name><surname>McPhillips</surname><given-names>T.</given-names></name>; <name><surname>Sauter</surname><given-names>N.</given-names></name>; <name><surname>Sharp</surname><given-names>K.</given-names></name>; <name><surname>Tsyba</surname><given-names>I.</given-names></name>; <name><surname>Wolf</surname><given-names>G.</given-names></name> (<year>2008</year>) <article-title>New paradigm
for macromolecular crystallography experiments at SSRL: Automated
crystal screening and remote data collection</article-title>. <source>Acta Crystallogr.</source>
<volume>D64</volume>, <fpage>1210</fpage>&#x02013;<lpage>1221</lpage>.</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Cohen</surname><given-names>A. E.</given-names></name>; <name><surname>Ellis</surname><given-names>P. J.</given-names></name>; <name><surname>Miller</surname><given-names>M. D.</given-names></name>; <name><surname>Deacon</surname><given-names>A. M.</given-names></name>; <name><surname>Phizackerley</surname><given-names>R. P.</given-names></name> (<year>2002</year>) <article-title>An automated
system to mount cryo-cooled protein crystals on a synchrotron beamline,
using compact sample cassettes and a small-scale robot</article-title>. <source>J. Appl. Crystallogr.</source>
<volume>35</volume>, <fpage>720</fpage>&#x02013;<lpage>726</lpage>.<pub-id pub-id-type="pmid">24899734</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>McPhillips</surname><given-names>T. M.</given-names></name>; <name><surname>McPhillips</surname><given-names>S. E.</given-names></name>; <name><surname>Chiu</surname><given-names>H. J.</given-names></name>; <name><surname>Cohen</surname><given-names>A. E.</given-names></name>; <name><surname>Deacon</surname><given-names>A. M.</given-names></name>; <name><surname>Ellis</surname><given-names>P. J.</given-names></name>; <name><surname>Garman</surname><given-names>E.</given-names></name>; <name><surname>Gonzalez</surname><given-names>A.</given-names></name>; <name><surname>Sauter</surname><given-names>N. K.</given-names></name>; <name><surname>Phizackerley</surname><given-names>R. P.</given-names></name>; <name><surname>Soltis</surname><given-names>S. M.</given-names></name>; <name><surname>Kuhn</surname><given-names>P.</given-names></name> (<year>2002</year>) <article-title>Blu-Ice and the Distributed
Control System: Software for data acquisition and instrument control
at macromolecular crystallography beamlines</article-title>. <source>J. Synchrotron Radiat.</source>
<volume>9</volume>, <fpage>401</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">12409628</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="book" id="cit43"><person-group person-group-type="allauthors"><name><surname>Gonzalez</surname><given-names>A.</given-names></name>, and <name><surname>Tsai</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>) <source>AUTOXDS</source>, <publisher-name>Stanford University</publisher-name>, <publisher-loc>Stanford, CA</publisher-loc>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Leslie</surname><given-names>A. G. W.</given-names></name>; <name><surname>Powell</surname><given-names>H. R.</given-names></name> (<year>2007</year>) <article-title>Processing Diffraction Data with Mosflm</article-title>. <source>Evolving Methods for Macromolecular Crystallography</source>
<volume>245</volume>, <fpage>41</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Project</surname><given-names>C. C.</given-names></name> (<year>1994</year>) <article-title>The CCP4
Suite: Programs for Protein Crystallography</article-title>. <source>Acta Crystallogr.</source>
<volume>D50</volume>, <fpage>760</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Gibson</surname><given-names>R. P.</given-names></name>; <name><surname>Tarling</surname><given-names>C. A.</given-names></name>; <name><surname>Roberts</surname><given-names>S.</given-names></name>; <name><surname>Withers</surname><given-names>S. G.</given-names></name>; <name><surname>Davies</surname><given-names>G. J.</given-names></name> (<year>2004</year>) <article-title>The donor
subsite of trehalose-6-phosphate synthase: Binary complexes with UDP-glucose
and UDP-2-deoxy-2-fluoro-glucose at 2 &#x000c5; resolution</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>1950</fpage>&#x02013;<lpage>1955</lpage>.<pub-id pub-id-type="pmid">14570926</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Matsumura</surname><given-names>H.</given-names></name>; <name><surname>Shiba</surname><given-names>T.</given-names></name>; <name><surname>Inoue</surname><given-names>T.</given-names></name>; <name><surname>Harada</surname><given-names>S.</given-names></name>; <name><surname>Kai</surname><given-names>Y.</given-names></name> (<year>1998</year>) <article-title>A novel mode
of target recognition suggested by the 2.0 &#x000c5; structure of holo
S100B from bovine brain</article-title>. <source>Structure</source>
<volume>6</volume>, <fpage>233</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">9519413</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Mccoy</surname><given-names>A. J.</given-names></name>; <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>; <name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Winn</surname><given-names>M. D.</given-names></name>; <name><surname>Storoni</surname><given-names>L. C.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name> (<year>2007</year>) <article-title>Phaser
crystallographic software</article-title>. <source>J. Appl. Crystallogr.</source>
<volume>40</volume>, <fpage>658</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">19461840</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Afonine</surname><given-names>P. V.</given-names></name>; <name><surname>Bunkoczi</surname><given-names>G.</given-names></name>; <name><surname>Chen</surname><given-names>V. B.</given-names></name>; <name><surname>Davis</surname><given-names>I. W.</given-names></name>; <name><surname>Echols</surname><given-names>N.</given-names></name>; <name><surname>Headd</surname><given-names>J. J.</given-names></name>; <name><surname>Hung</surname><given-names>L. W.</given-names></name>; <name><surname>Kapral</surname><given-names>G. J.</given-names></name>; <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>; <name><surname>McCoy</surname><given-names>A. J.</given-names></name>; <name><surname>Moriarty</surname><given-names>N. W.</given-names></name>; <name><surname>Oeffner</surname><given-names>R.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name>; <name><surname>Richardson</surname><given-names>D. C.</given-names></name>; <name><surname>Richardson</surname><given-names>J. S.</given-names></name>; <name><surname>Terwilliger</surname><given-names>T. C.</given-names></name>; <name><surname>Zwart</surname><given-names>P. H.</given-names></name> (<year>2010</year>) <article-title>PHENIX: A comprehensive Python-based
system for macromolecular structure solution</article-title>. <source>Acta Crystallogr.</source>
<volume>D66</volume>, <fpage>213</fpage>&#x02013;<lpage>221</lpage>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Emsley</surname><given-names>P.</given-names></name>; <name><surname>Lohkamp</surname><given-names>B.</given-names></name>; <name><surname>Scott</surname><given-names>W. G.</given-names></name>; <name><surname>Cowtan</surname><given-names>K.</given-names></name> (<year>2010</year>) <article-title>Features and development
of Coot</article-title>. <source>Acta Crystallogr.</source>
<volume>D66</volume>, <fpage>486</fpage>&#x02013;<lpage>501</lpage>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="book" id="cit51"><person-group person-group-type="allauthors"><name><surname>Afonine</surname><given-names>P. V.</given-names></name>, <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>, and <name><surname>Adams</surname><given-names>P. D.</given-names></name></person-group> (<year>2005</year>) <article-title>The Phenix Refinement Framework</article-title>,. <source>CCP4 Newsletter</source>, Vol. <volume>42</volume>, Contribution
8, <publisher-name>Daresbury Laboratory</publisher-name>, <publisher-loc>Warrington, U.K.</publisher-loc></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Hartman</surname><given-names>K. G.</given-names></name>; <name><surname>Vitolo</surname><given-names>M. I.</given-names></name>; <name><surname>Pierce</surname><given-names>A. D.</given-names></name>; <name><surname>Fox</surname><given-names>J. M.</given-names></name>; <name><surname>Shapiro</surname><given-names>P.</given-names></name>; <name><surname>Martin</surname><given-names>S. S.</given-names></name>; <name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2014</year>) <article-title>Complex Formation
between S100B Protein and the p90 Ribosomal S6 Kinase (RSK) in Malignant
Melanoma Is Calcium-dependent and Inhibits Extracellular Signal-regulated
Kinase (ERK)-mediated Phosphorylation of RSK</article-title>. <source>J. Biol. Chem.</source>
<volume>289</volume>, <fpage>12886</fpage>&#x02013;<lpage>12895</lpage>.<pub-id pub-id-type="pmid">24627490</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Bachman</surname><given-names>K. E.</given-names></name>; <name><surname>Sager</surname><given-names>J.</given-names></name>; <name><surname>Cheong</surname><given-names>I.</given-names></name>; <name><surname>Catto</surname><given-names>M.</given-names></name>; <name><surname>Bardelli</surname><given-names>A.</given-names></name>; <name><surname>Park</surname><given-names>B. H.</given-names></name>; <name><surname>Vogelstein</surname><given-names>B.</given-names></name>; <name><surname>Carotti</surname><given-names>A.</given-names></name>; <name><surname>Kinzler</surname><given-names>K. W.</given-names></name>; <name><surname>Lengauer</surname><given-names>C.</given-names></name> (<year>2005</year>) <article-title>Identification of compounds that inhibit growth of
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells</article-title>. <source>Mol. Cancer Ther.</source>
<volume>4</volume>, <fpage>1026</fpage>&#x02013;<lpage>1030</lpage>.<pub-id pub-id-type="pmid">15956261</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Myers</surname><given-names>M. A.</given-names></name> (<year>1998</year>) <article-title>Direct
measurement of cell numbers in microtitre plate cultures using the
fluorescent dye SYBR green I</article-title>. <source>J. Immunol. Methods</source>
<volume>212</volume>, <fpage>99</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">9671157</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Sauna</surname><given-names>Z. E.</given-names></name>; <name><surname>Peng</surname><given-names>X. H.</given-names></name>; <name><surname>Nandigama</surname><given-names>K.</given-names></name>; <name><surname>Tekle</surname><given-names>S.</given-names></name>; <name><surname>Ambudkar</surname><given-names>S. V.</given-names></name> (<year>2004</year>) <article-title>The molecular
basis of the action of disulfiram as a modulator of the multidrug
resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and
MRP1 (ABCC1)</article-title>. <source>Mol. Pharmacol.</source>
<volume>65</volume>, <fpage>675</fpage>&#x02013;<lpage>684</lpage>.<pub-id pub-id-type="pmid">14978246</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Wilder</surname><given-names>P. T.</given-names></name>; <name><surname>Baldisseri</surname><given-names>D. M.</given-names></name>; <name><surname>Udan</surname><given-names>R.</given-names></name>; <name><surname>Vallely</surname><given-names>K. M.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2003</year>) <article-title>Location
of the Zn<sup>2+</sup>-binding site on S100B as determined by NMR
spectroscopy and site-directed mutagenesis</article-title>. <source>Biochemistry</source>
<volume>42</volume>, <fpage>13410</fpage>&#x02013;<lpage>13421</lpage>.<pub-id pub-id-type="pmid">14621986</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Wilder</surname><given-names>P.
T.</given-names></name>; <name><surname>Varney</surname><given-names>K. M.</given-names></name>; <name><surname>Weiss</surname><given-names>M. B.</given-names></name>; <name><surname>Gitti</surname><given-names>R. K.</given-names></name>; <name><surname>Weber</surname><given-names>D. J.</given-names></name> (<year>2005</year>) <article-title>Solution
structure of zinc- and calcium-bound rat S100B as determined by nuclear
magnetic resonance spectroscopy</article-title>. <source>Biochemistry</source>
<volume>44</volume>, <fpage>5690</fpage>&#x02013;<lpage>5702</lpage>.<pub-id pub-id-type="pmid">15823027</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Cremer</surname><given-names>D.</given-names></name>; <name><surname>Hausen</surname><given-names>B. M.</given-names></name>; <name><surname>Schmalle</surname><given-names>H. W.</given-names></name> (<year>1987</year>) <article-title>Toward
a rationalization of the sensitizing
potency of substituted p-benzoquinones: Reaction of nucleophiles with
p-benzoquinones</article-title>. <source>J. Med. Chem.</source>
<volume>30</volume>, <fpage>1678</fpage>&#x02013;<lpage>1681</lpage>.<pub-id pub-id-type="pmid">3625712</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Mather</surname><given-names>B. D.</given-names></name>; <name><surname>Viswanathan</surname><given-names>K.</given-names></name>; <name><surname>Miller</surname><given-names>K. M.</given-names></name>; <name><surname>Long</surname><given-names>T. E.</given-names></name> (<year>2006</year>) <article-title>Michael addition
reactions in macromolecular design for emerging technologies</article-title>. <source>Prog. Polym. Sci.</source>
<volume>31</volume>, <fpage>487</fpage>&#x02013;<lpage>531</lpage>.</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Lou</surname><given-names>H.</given-names></name>; <name><surname>Ookhtens</surname><given-names>M.</given-names></name>; <name><surname>Stolz</surname><given-names>A.</given-names></name>; <name><surname>Kaplowitz</surname><given-names>N.</given-names></name> (<year>2003</year>) <article-title>Chelerythrine
stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney
cells</article-title>. <source>Am. J. Physiol.</source>
<volume>285</volume>, <fpage>G1335</fpage>&#x02013;<lpage>G1344</lpage>.</mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Jemal</surname><given-names>A.</given-names></name>; <name><surname>Murray</surname><given-names>T.</given-names></name>; <name><surname>Samuels</surname><given-names>A.</given-names></name>; <name><surname>Ghafoor</surname><given-names>A.</given-names></name>; <name><surname>Ward</surname><given-names>E.</given-names></name>; <name><surname>Thun</surname><given-names>M. J.</given-names></name> (<year>2003</year>) <article-title>Cancer statistics,
2003</article-title>. <source>Ca-Cancer
J. Clin.</source>
<volume>53</volume>, <fpage>5</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">12568441</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Abraha</surname><given-names>H.
D.</given-names></name>; <name><surname>Fuller</surname><given-names>L. C.</given-names></name>; <name><surname>Du Vivier</surname><given-names>A. W.</given-names></name>; <name><surname>Higgins</surname><given-names>E. M.</given-names></name>; <name><surname>Sherwood</surname><given-names>R. A.</given-names></name> (<year>1997</year>) <article-title>Serum S-100
protein: A potentially useful prognostic marker in cutaneous melanoma</article-title>. <source>Br. J. Dermatol.</source>
<volume>137</volume>, <fpage>381</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">9349333</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Banfalvi</surname><given-names>T.</given-names></name>; <name><surname>Gilde</surname><given-names>K.</given-names></name>; <name><surname>Gergye</surname><given-names>M.</given-names></name>; <name><surname>Boldizsar</surname><given-names>M.</given-names></name>; <name><surname>Kremmer</surname><given-names>T.</given-names></name>; <name><surname>Otto</surname><given-names>S.</given-names></name> (<year>2003</year>) <article-title>Use of serum 5-S-CD and S-100B protein
levels to monitor the clinical course of malignant melanoma</article-title>. <source>Eur. J. Cancer</source>
<volume>39</volume>, <fpage>164</fpage>&#x02013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">12509947</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Buer</surname><given-names>J.</given-names></name>; <name><surname>Probst</surname><given-names>M.</given-names></name>; <name><surname>Franzke</surname><given-names>A.</given-names></name>; <name><surname>Duensing</surname><given-names>S.</given-names></name>; <name><surname>Haindl</surname><given-names>J.</given-names></name>; <name><surname>Volkenandt</surname><given-names>M.</given-names></name>; <name><surname>Wittke</surname><given-names>F.</given-names></name>; <name><surname>Hoffmann</surname><given-names>R.</given-names></name>; <name><surname>Ganser</surname><given-names>A.</given-names></name>; <name><surname>Atzpodien</surname><given-names>J.</given-names></name> (<year>1997</year>) <article-title>Elevated serum levels of S100 and survival in metastatic
malignant melanoma</article-title>. <source>Br. J. Cancer</source>
<volume>75</volume>, <fpage>1373</fpage>&#x02013;<lpage>1376</lpage>.<pub-id pub-id-type="pmid">9155061</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Djukanovic</surname><given-names>D.</given-names></name>; <name><surname>Hofmann</surname><given-names>U.</given-names></name>; <name><surname>Sucker</surname><given-names>A.</given-names></name>; <name><surname>Rittgen</surname><given-names>W.</given-names></name>; <name><surname>Schadendorf</surname><given-names>D.</given-names></name> (<year>2000</year>) <article-title>Comparison
of S100 protein and MIA protein as serum marker for malignant melanoma</article-title>. <source>Anticancer Res.</source>
<volume>20</volume>, <fpage>2203</fpage>&#x02013;<lpage>2207</lpage>.<pub-id pub-id-type="pmid">10928178</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Guo</surname><given-names>H. B.</given-names></name>; <name><surname>Stoffel-Wagner</surname><given-names>B.</given-names></name>; <name><surname>Bierwirth</surname><given-names>T.</given-names></name>; <name><surname>Mezger</surname><given-names>J.</given-names></name>; <name><surname>Klingmuller</surname><given-names>D.</given-names></name> (<year>1995</year>) <article-title>Clinical significance
of serum S100 in metastatic malignant melanoma</article-title>. <source>Eur. J. Cancer</source>
<volume>31A</volume>, <fpage>1898</fpage>&#x02013;<lpage>1902</lpage>.<pub-id pub-id-type="pmid">8541129</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Karnell</surname><given-names>R.</given-names></name>; <name><surname>von Schoultz</surname><given-names>E.</given-names></name>; <name><surname>Hansson</surname><given-names>L. O.</given-names></name>; <name><surname>Nilsson</surname><given-names>B.</given-names></name>; <name><surname>Arstrand</surname><given-names>K.</given-names></name>; <name><surname>Kagedal</surname><given-names>B.</given-names></name> (<year>1997</year>) <article-title>S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic
acid as biochemical markers for survival prognosis in patients with
malignant melanoma</article-title>. <source>Melanoma Res.</source>
<volume>7</volume>, <fpage>393</fpage>&#x02013;<lpage>399</lpage>.<pub-id pub-id-type="pmid">9429222</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Mohammed</surname><given-names>A. A.</given-names></name>; <name><surname>Januzzi</surname><given-names>J. L.</given-names><suffix>Jr.</suffix></name> (<year>2010</year>) <article-title>Clinical applications of highly sensitive
troponin assays</article-title>. <source>Cardiol. Rev.</source>
<volume>18</volume>, <fpage>12</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">20010334</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Levine</surname><given-names>A. J.</given-names></name> (<year>1997</year>) <article-title>p53, the
cellular gatekeeper for growth and division</article-title>. <source>Cell</source>
<volume>88</volume>, <fpage>323</fpage>&#x02013;<lpage>331</lpage>.<pub-id pub-id-type="pmid">9039259</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Kohler</surname><given-names>J.</given-names></name>; <name><surname>Schuler</surname><given-names>M.</given-names></name> (<year>2014</year>) <article-title>LUX-Lung 3: Redundancy,
toxicity or a major step forward?
Afatinib as front-line therapy for patients with metastatic EGFR-mutated
lung cancer</article-title>. <source>Future Oncol.</source>
<volume>10</volume>, <fpage>533</fpage>&#x02013;<lpage>540</lpage>.<pub-id pub-id-type="pmid">24754585</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Serafimova</surname><given-names>I. M.</given-names></name>; <name><surname>Pufall</surname><given-names>M. A.</given-names></name>; <name><surname>Krishnan</surname><given-names>S.</given-names></name>; <name><surname>Duda</surname><given-names>K.</given-names></name>; <name><surname>Cohen</surname><given-names>M. S.</given-names></name>; <name><surname>Maglathlin</surname><given-names>R. L.</given-names></name>; <name><surname>McFarland</surname><given-names>J. M.</given-names></name>; <name><surname>Miller</surname><given-names>R. M.</given-names></name>; <name><surname>Frodin</surname><given-names>M.</given-names></name>; <name><surname>Taunton</surname><given-names>J.</given-names></name> (<year>2012</year>) <article-title>Reversible targeting
of noncatalytic cysteines with
chemically tuned electrophiles</article-title>. <source>Nat. Chem. Biol.</source>
<volume>8</volume>, <fpage>471</fpage>&#x02013;<lpage>476</lpage>.<pub-id pub-id-type="pmid">22466421</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Erlanson</surname><given-names>D. A.</given-names></name>; <name><surname>Wells</surname><given-names>J. A.</given-names></name>; <name><surname>Braisted</surname><given-names>A. C.</given-names></name> (<year>2004</year>) <article-title>Tethering:
Fragment-based drug discovery</article-title>. <source>Annu. Rev. Biophys.
Biomol. Struct.</source>
<volume>33</volume>, <fpage>199</fpage>&#x02013;<lpage>223</lpage>.<pub-id pub-id-type="pmid">15139811</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Potashman</surname><given-names>M. H.</given-names></name>; <name><surname>Duggan</surname><given-names>M. E.</given-names></name> (<year>2009</year>) <article-title>Covalent modifiers: An orthogonal approach to drug
design</article-title>. <source>J. Med. Chem.</source>
<volume>52</volume>, <fpage>1231</fpage>&#x02013;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">19203292</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Lim</surname><given-names>S. Y.</given-names></name>; <name><surname>Raftery</surname><given-names>M. J.</given-names></name>; <name><surname>Goyette</surname><given-names>J.</given-names></name>; <name><surname>Hsu</surname><given-names>K.</given-names></name>; <name><surname>Geczy</surname><given-names>C. L.</given-names></name> (<year>2009</year>) <article-title>Oxidative
modifications of S100 proteins: Functional regulation by redox</article-title>. <source>J. Leukocyte Biol.</source>
<volume>86</volume>, <fpage>577</fpage>&#x02013;<lpage>587</lpage>.<pub-id pub-id-type="pmid">19237640</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Meghnani</surname><given-names>V.</given-names></name>; <name><surname>Vetter</surname><given-names>S. W.</given-names></name>; <name><surname>Leclerc</surname><given-names>E.</given-names></name> (<year>2014</year>) <article-title>RAGE overexpression confers a metastatic
phenotype to the WM115 human primary melanoma cell line</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1842</volume>, <fpage>1017</fpage>&#x02013;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">24613454</pub-id></mixed-citation></ref></ref-list></back></article>